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Abstract 
Aim: The aim of this study was to explore the relationships between demographic and 
clinical variables, and multiple symptoms such as breathlessness, depression, anxiety, 
fatigue, insomnia and pain in COPD.  
 
Background: Although research in COPD often has focused on single symptoms there 
is a lack of knowledge about possible associations with multiple symptoms.  
 
Methods: A total of 154 COPD patients participated in a cross-sectional study from 
June 2006 to December 2007.  All performed pulmonary lung function tests and 
completed a questionnaire that included demographic variables, Brief Pain Inventory, 
Hospital Anxiety and Depression Scale, Lee Fatigue Scale, General Sleep Disturbance 
Scale and Respiratory Quality of Life Questionnaire. Co-morbidity and medication 
were collected from their medical records. The following analysis method was used: 
descriptive, bivariate correlation and multiple regression analysis.  
 
Results:  With regard to demographic variables, age was significantly related to 
breathlessness, fatigue, insomnia and pain. Education was significantly related to 
depression and anxiety. Smoking was significantly related to anxiety, depression and 
pain. Co-morbidity was significantly related to breathlessness. 
Bivariate relationships showed that breathlessness, depression, anxiety, fatigue, 
insomnia and pain were significantly related to each other. In the multiple regression 
analysis, lung function was related to breathlessness and insomnia. Breathlessness was 
the most significant symptom associated with the other symptoms after controlling for 
demographic and clinical variables. 
 
Conclusion: Breathlessness is a significant symptom associated with depression, 
anxiety, fatigue, insomnia and pain. Results from this study may suggest an expanded 
focus on multiple symptoms in COPD guidelines, health care and research. 
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Sammendrag 
Mål: Målet med studien var å undersøke sammenhengen mellom tung pust, depresjon, 
angst, trøtthet, søvnvansker og smerte hos personer med KOLS                                                
                                                                                                                                           
Bakgrunn: Forskning innen KOLS har primært fokusert på ett symptom av gangen, 
men det er lite kunnskap om mulige sammenhenger mellom flere symptomer. 
Teoretisk rammeverk som symptomhåndteringsmodellen kan gi innsikt i forståelsen av 
ulike sammenhenger mellom symptomer. 
 
Metode: Totalt deltok 154 personer med KOLS i tverrsnittstudien i perioden juni 
2006-desember 2007. Alle gjennomførte lungefunksjonstest og fylte ut spørreskjema 
som inkluderte demografiske variable, Brief Pain Inventory, Hospital Anxiety and 
Depression Scale, Lee Fatigue Scale, General Sleep Disturbance Scale og Respiratory 
Quality of Life Questionnaire.  Informasjon om sykdommer og medisiner ble hentet 
fra journal. Følgende analysemetoder ble benyttet: deskriptiv statistikk, bivariate 
korrelasjonsanalyse og multiregresjonsanalyser. 
 
Resultat: Alder viste signifikant sammenheng med tung pust, trøtthet, søvnvansker og 
smerte. Utdannelse viste signifikant sammenheng med depresjon og angst. Røyking 
viste signifikant sammenheng med angst, depresjon og smerte. Antall sykdommer 
viste signifikant sammenheng med tung pust. 
Bivariate korrelasjon viste at tung pust, depresjon, angst, trøtthet, søvnvansker og 
smerte var signifikant assosiert med hverandre. I multiregresjonsanalysen hadde 
lungefunksjon sammenheng med tung pust og søvnvansker. Tung pust viste størst 
signifikant sammenheng med de andre symptomene etter å ha kontrollert for 
demografiske og kliniske variable. 
 
Konklusjon: Tung pust er det mest fremtredende symptomet hos personer med KOLS 
og viser sammenheng mellom symptomer som depresjon, angst, trøtthet, søvnvansker 
og smerte.  Resultatene fra studien tilsier at det kan være formålstjenlig å fokusere mer 
på multisymptomer i guidelines, behandling og forskning.  
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1. Introduction 
Chronic Obstructive Pulmonary Disease (COPD) is known to be a slowly progressive 
disorder with airflow obstruction that does not change (Bourke, 2007). Smoking over 
time can bring on this obstruction. Until recently there has not been much focus on 
COPD, even though the term COPD has been known since 1959 (Rabe, et al., 2007). 
Few people have been familiar with this diagnosis and the consequences smoking has 
had for it (Petty, 2006). It is estimated that a total of 5.4% (about 200 000) of the 
Norwegian population suffers from COPD (Helse-og omsorgsdepartementet, 2006). 
World wide there is estimated to be 80 million people with COPD. Morbidity and 
mortality are a major result of the disease, and the situation is expected to get worse in 
the future (Hurd, 2000). COPD is also stated to be a costly disease for the health 
service (Rabe, et al., 2007).  
 
Global Initiative for Chronic obstructive Lung Disease (GOLD) (Rabe, et al., 2007) 
and American Thoracic Society (ATS) Standard for the Diagnosis and Management of 
Patients with COPD (ATS/ERS guidelines, 2004) are guidelines that are used in 
diagnosing and helping COPD patients. These guidelines have narrow focus on 
symptoms other than disease characteristics as breathlessness, dyspnea and sputum 
(Walke, et al., 2007). However the patients themselves subjectively may feel they have 
got several symptoms. Clinically it is difficult to treat and help COPD patients to live 
well with their chronic disease. Would it help if the health service to a greater extent 
could focus on psychosocial symptoms? 
 
Studies show that lung function signs such as FEV1 have less or no association with 
symptoms of psychological and social characteristics. Dyspnea is almost the only 
symptom found to be  associated with  FEV1 (Mahler, et al., 1992). Dyspnea has 
however shown an association with  depression (Kellner, et al., 1992). Another study 
reports that  FEV1 correlated with dyspnea and physical function but not with anxiety 
(Cully, et al., 2006).  Depression and anxiety are also often found to be of close 
association (Mikkelsen, et al., 2004).  Both insomnia (Kutty, 2004) and fatigue 
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(Theander, et al., 2004) have been reported as highly relevant symptoms in COPD. 
The amount of 32.2% of persons with end stage COPD have reported pain (Rabow, et 
al., 2005). Although the symptom pain has not been much focused in COPD science, 
one study has shown that breathing difficulties have a relationship with pain using a 
health quality of life questionnaire. Predicted FEV1 and pain showed no significance 
in the same study (Mahler, et al., 1995). 
 
The studies mentioned above illustrate that most of the research on symptoms in 
COPD have been directed towards one single symptom or a few symptoms in one and 
the same study.  Actually only one study has focused on the symptoms dyspnea, 
anxiety, depression, fatigue and sleeping problems in COPD (Kapella, et al., 2006).  
The symptoms dyspnea, depression, anxiety, insomnia, fatigue and pain in COPD have 
never been investigated in one and the same study. 
 
Understanding and management of symptoms is complex. One symptom could 
influence other symptoms and several factors could have an impact (Miaskowski, et 
al., 2007).  Different models have been developed to understand symptoms. The 
Symptom Management Model is a theoretical framework  that may help understanding 
symptoms in a biopsychosocial approach (Dodd, et al., 2001a).  This model is based 
on earlier research in oncology (Dodd, et al., 2001a). 
 
We know from studies in oncology  that multiple symptoms as pain, fatigue and 
depression are associated (Dodd, et al., 2004). Reports show that multiple symptoms 
are influenced by demographic variables and sickness characteristics (Miaskowski, et 
al., 2006). This kind of association may also be found in COPD.                                                    
 
To be able to meet the challenge of helping COPD patients with their problems, we 
need to know more about multiple symptoms. Focusing on multiple symptoms could 
help us understand more about their special nature and combinations. This would 
improve our knowledge about the association with possible signs of illness and the 
different demographic variables in COPD.                                                                                  
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On this background this study will focus on multiple symptoms in COPD such as 
breathlessness, depression, anxiety, insomnia, fatigue and pain.  
1.1 Research question 
Through an explorative study we searched for an answer to the question:                       
 
1. What is the relationship between the demographic variables smoking, co-morbidity 
and lung function and multiple symptoms (breathlessness, depression, anxiety, 
insomnia, fatigue and pain)? 
 
2. What is the relationship between breathlessness and depression, anxiety, insomnia, 
fatigue and pain, controlling for demographic and clinical variables? 
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2. Theoretical background 
 
2.1 Chronic obstructive Pulmonary Disease (COPD) 
 
Global Initiative for Chronic Obstructive Lung Disease (GOLD) was established in 
1998. They have defined Chronic Obstructive Pulmonary Disease as characterized by 
airflow obstruction that is not fully reversible. The term implies two diseases: 
obstructive bronchitis and emphysema (Rabe, et al., 2007).                                                                                                                       
It has been stated that in some individuals with fixed airflow limitation it is difficult to 
differentiate asthma from COPD (Rabe, et al., 2007). The main difference is that 
Asthma has periods free from symptoms and shows normal spirometry values. COPD 
has more chronic characteristics of the symptoms breathlessness, cough, sputum, and it 
has seldom variable spirometry values. Asthma is believed to be more genetically 
related than COPD (Bourke, 2007). The study by Charles Fletcher in 1977 showed that 
smoking was the main reason for chronic airflow obstruction (Fletcher, et al., 1977).  
Recently other thoughts have been stated. One study shows that genetic factors 
independent of those related to smoking habits  can play a role in development of 
chronic bronchitis (Hallberg, et al., 2007).                                                                           
 
Because of the difficulties of distinguishing asthma from COPD, COPD has often been 
described as an umbrella term that includes chronic bronchitis, emphysema and 
chronic asthmatic bronchitis. Asthma is then described as a hyper responsiveness to a 
variety of stimuli in the airways (Petty, 2006), differing from COPD in pathology and 
clinical characteristics (Bourke, 2007). Chronic asthmatic bronchitis is in this way 
considered an overlapping diagnosis, but with different physiological mechanisms 
(Petty, 2006).   
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Chronic bronchitis implies that inflammation cells in the airways can lead to mucus 
hyper secretion, ciliary dysfunction and airflow limitation. The result is small airways 
causing airflow obstruction. This can again bring on hard breathing, cough and sputum 
(Bourke, 2007).            
 
Emphysema involves a destruction of the small airways and the alveoli. Loss of 
elasticity can lead to collapse. The gas exchange between the alveoli and the blood can 
be altered. When the oxygen levels in the body fall, the respiratory centre in the brain 
reacts with dyspnoea (Bourke, 2007). 
 
 Some people with asthma develop fixed airflow obstruction. The reason for these 
changes is among other things mucous membrane thickening and increased airway 
smooth muscle. This can lead to the feeling of dyspnoea, cough and sputum. (Bourke, 
2007) 
 
The diagnosis of COPD is done by performing a lung function test, spirometry. 
Spirometry values with the combination of FEV1/FVC (FEV %) (4.3.1).should be 
under 70% before taking a bronchodilator. In order to confirm the diagnosis, 
information about medical history on dyspnoea, chronic cough, chronic sputum 
production and exposure to risk factors such as tobacco, dusts, chemical smoke from 
home cooking and heating fuels should also be considered (Rabe, et al., 2007).  
FEV1(4.3.1)  is used to classify severity of COPD. GOLD has classified COPD in 4 
stages:   
• Stage I: Mild  FEV1/FVC<70% , FEV1 ≥80% predicted   
• Stage II: Moderate         FV1/FVC <70%, 50% ≤ FEV1<80% predicted 
• Stage III: Severe FEV1/FVC <70%, 30% ≤ FEV1<50% predicted 
• Stage IV: Very Severe FEV1/FVC <70%, FEV1<30% predicted or FEV1<50% 
predicted plus chronic respiratory failure  (Rabe, et al., 2007)                                                                               
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2.2 Definition of symptom, multiple symptoms,                          
symptomcluster and sign  
 
Symptom                                                                                                                                 
The word “symptom” descends from Greek “to fall” and “together”. In the 19th century 
it was described as the bodily or mental phenomena that a person experiences 
(Aronowitz, 2001). The sense of the definition has not been changed very much since 
the 19th century. It still implies the subjective phenomena. “Symptom” is experienced 
by the person himself.  One definition of the term symptom is: “subjective experience 
reflecting changes in the biospychosocial functioning, sensations or cognition of an 
individual” (Dodd, et al., 2001a, p.669). The definition states a subjective feeling that 
could be associated with thoughts or with a feeling of changes in the body. This could 
for instance be the feeling of breathlessness as a result of obstruction in the airways 
(ATS/ERS guidelines, 2004). Symptom could also be changes of psychological 
function such as depression and anxiety and of sociological function as loneliness 
(Kara, et al., 2004).    
 
Sign                                                                                                                                              
The term sign was in the 19th century described objectively (Aronowitz, 2001). Today 
the definition is still objective, but it also contains information that the person himself 
can detect. The term sign has been defined as  “any abnormality indicative of disease 
that is detectable by the individual or by others” (Dodd, et al., 2001a, p.669). This 
could be blue lips with dyspnoea or a lung function test as predicted FEV1.  
 
Multiple symptoms                                                                                                                             
It is necessary to understand the meaning of the concept “multiple”, in order to be able 
to describe the sense of “multiple symptoms”. Webster’s Dictionary defines the 
concept multiple as “having numerous aspects or functions” and “ more than one” 
(Webster dictionary, 1983, p.779). Multiple symptoms could thus be understood as 
several symptoms detected by the person himself. However they are not necessarily 
synonymous.  A person with COPD could for instance suffer from both dyspnea and 
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depression where dyspnea could be due to the disease and depression could be caused 
by a social situation, such as financial difficulties.  
 
Symptom cluster                                                                                                                       
The term symptom cluster has a similar explanation as the concept multiple symptoms. The 
term symptom cluster is by Dodd et. al defined as three or more symptoms associated with 
each other and sharing the same variance. The symptoms in the cluster don’t have to share the 
same mechanisms (Dodd, et al., 2004,p.465). This means that the cause of the symptoms 
could be different. In oncology patients fatigue can for instance be due to medication 
connected with treatment, pain caused by the disease and insomnia caused by pain. They then 
don’t share the same mechanisms, but the symptoms could still be associated with each other 
in a cluster and share an explaining variance. Symptom cluster differs in this way from 
multiple symptoms by the amount of symptoms (being three symptoms or more) and by the 
fact that symptoms in a cluster should share the same explaining variance. 
 
2.3 Definition of the concept: breathlessness, 
depression, anxiety, fatigue, insomnia and pain  
The symptoms breathlessness, depression, anxiety, fatigue, insomnia and pain focused 
in this thesis can be described and defined in a different perspective. Several of these 
symptoms are often known as names of diseases. Depression for instance is one of the 
most prevalent disorders (Passer, et al., 2008), while generalized anxiety disorder has 
been found in 5% of people between 15-45 years old (Passer, et al., 2008) and chronic 
fatigue syndrome has the recent years been more known as a disease (Soderlund, et al., 
2005).  These sensations may be representative of a pathological state. Likewise 
breathlessness is known to be a symptom both in heart disorders and lung disorders. 
The exact difference between symptom and disease will in many circumstances be 
difficult to distinguish. The actual definition of symptoms concepts is complex and can 
be described in a biological, psychological and/or sociological perspective. In this 
study the persons own experience of the symptoms will be in focus.  
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Breathlessness                                                                                                                                     
Dyspnea has been defined as the “sensation of difficulty of  breathing” (Janssens, et 
al., 2000,p.379). Historically in many Greek texts asthma was described as abnormal 
breathing. During the 19th and 20th centuries asthma was reformulated from a 
symptomatic diagnosis to the name of a disease (Aronowitz, 2001).                                                          
Other words for dyspnea used in literature, by patients and health care are 
breathlessness and shortness of breath (Lindsey, et al., 1993). These words will be 
used synonymously in this master thesis.                                                                 
Breathlessness or dyspnoea is probably the symptom mostly used within respiratory 
disease (Ambrosino, et al., 2004).  The concept is a subjective experience of 
difficulties and uncomfortable breathing with a sensation of breathing problems and 
unpleasant stimuli (Lindsey, et al., 1993).  The definition includes a personal reaction 
as well as a subjective experience.  
 
Dyspnea often occurs with activity as light house work (Isoaho, et al., 1995), shopping 
and eating (Odencrants, et al., 2005). Dyspnea is often trigged by  smoke-filled rooms, 
stress, environmental factors as weather, pollution, allergens and dust (Lindsey, et al., 
1993). It can be difficult to avoid situations like these and the sensation of 
breathlessness can happen unexpectedly. Inability to manage active and social 
situations may cause hopelessness and loneliness. These situations can lead to 
immobility that may bring on worse attacks of breathlessness (Kara, et al., 2004). The 
subjective experience of breathlessness has been described as invisible symptoms and 
may be recognized by anxiety symptoms (Bailey, 2004). Continual respiratory 
infections often involve more breathlessness and can make the disease more severe 
(Wedzicha, et al., 2003). These are all subjective experiences of breathing difficulties 
that occur with different stimuli.                                                               
 
Depression                                                                                                                                   
Depression is by Websters dictionary defined as “a state of feeling sad”                  
(Webster dictionary, 1983, p.341). Sad is defined as  “affected with or expressive of 
grief or unhappiness “ (Webster dictionary, 1983, p.1035).  
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The definition of the concept involves the person’s sensation of feeling unwell. This 
could be caused by a sense of loss or worthlessness, lack of support, anger, a feeling of 
helplessness or a negative self image. Most people experience depression symptoms 
like these from time to time in life (Atkinson, et al., 1990).                                                                                                                  
COPD patients can to a great extent feel that they have lost control of their lives. 
Friends and family who are healthy might react to their depressive symptoms and may 
withdraw from the depressed person (Kara, et al., 2004).                                                                                                               
A lot of people with COPD have smoked or are still in the habit of smoking.  People 
with COPD can have a negative self image due to shame from smoking or having 
smoked. This might be the reason why people with COPD do not seek medical help 
(Arne, et al., 2007).  
 
The intensity and occurrence of depression symptoms over a long period could explain 
clinical depression. However, the specific definition of what is normal or abnormal 
behavior is vital in order to explain the difference of what is symptom and what is 
disease. “Abnormal behavior is statistically infrequent or deviant from the norm” 
(Atkinson, et al., 1990,p.591). A norm is usually a behavior in a certain society.  
Abnormality occurs when people don’t recover when expected (Atkinson, et al., 
1990).                                                                 
 
Anxiety                                                                                                                                
Anxiety is defined as “an emotional state characterized by apprehension accompanied 
by physiological arousal and fearful behaviour”(Passer, et al., 2008, p.G-1).  
An interpretation of the definition anxiety could imply a subjective experience of a 
physiological symptom.  The feeling of physical sensations such as heart beat, chest 
pain, nausea, dyspnoea and headaches are anxiety symptoms. Anxiety can be trigged 
by fearful and threatening situations. This could be crowds gathered for instance at 
school or in other social situations. Anxiety can also occur when the person feels 
unable to cope with everyday settings (Atkinson, et al., 1990).  Cognitive processes 
such as thoughts involving worries and threats can also give anxiety symptoms 
(Passer, et al., 2008). The anxiety-dyspnea circle illustrates that people who can not 
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breathe get anxiety symptoms causing more breathlessness (Bailey, 2004). 
Remembering an anxiety situation can lead to  anxiety symptoms (Passer, et al., 2008).  
When anxiety happens in a situation that most people can handle it is considered 
abnormal and could be an anxiety disorder. In a stressful or threatening situation where 
most people feel anxiety this may however be a symptom (Atkinson, et al., 1990). 
 
Depression and anxiety symptoms can often overlap, but it has also been stated that 
not everyone with depression symptoms experiences the same levels of anxiety 
(Sitsen, et al., 2003). In fact research has found both situations in COPD                        
(Kellner, et al., 1992).                                                                      
 
Insomnia                                                                                                                               
Insomnia is defined as a “symptom complex consisting of difficulty falling asleep, or 
staying asleep, or non refreshing sleep in combination with some form of daytime 
squealae” (Roth, et al., 2003,p.5).  
Subjectively this definition implies that insomnia is a symptom caused by 
dissatisfaction with impaired sleep. It could mean that lack of sleep involves tiredness 
or not being able to sleep as long as wanted or having a satisfactory period of sleep all 
night.   
 
Environmental factors such as light and noise can give impaired sleep. Personal 
worries can interfere with sleep and be the reason for insomnia. This can be due to 
acute situations as death in the family, conflicts at work, with family or friends, or 
worries about personal health. It is well known that psychological factors like 
depression, anxiety and poor quality of life can interfere with sleep quality                   
(Kutty, 2004;Roth, et al., 2003). In fact the most common co- morbidity found among 
insomnia patients are psychiatric disorders. Insomnia can lead to fatigue, daytime 
sleepiness, short memory, impaired problem solving/coping (Lindsey, et al., 1993) The 
symptoms cough, mucus and breathlessness in COPD may give episodes of nocturnal 
dyspnea and frequent awareness (Roth, et al., 2003). The disruption in gas 
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exchange between the alveoli and blood in emphysema may increase ventilation, give 
hypoxemia and then disturb sleep (George, et al., 2003). Also medications such as 
corticosteroids and β-agonists are known to cause insomnia problems (Kutty, 2004).                  
 
Fatigue                                                                                                                                     
Fatigue has been defined as “an overwhelming sustained sense of exhaustion and 
decreased capacity for physical and mental work” (Lindsey, et al., 1993,p.209).  
From this definition fatigue implies a sensation of being very tired and not being able 
to concentrate, remember, think clearly, direct attention and cognitively perform 
different tasks (Lindsey, et al., 1993). Physical fatigue can involve different parts of 
the body. This can be a feeling of tiredness in legs when walking or in breathing 
muscles as a result of heavy breathing in COPD (Lindsey, et al., 1993).  
 
A lot of circumstances can cause fatigue. This can be side effects of medication, 
diseases like multiple sclerosis, rheumatoid arthritis, cancer, AIDS , chronic fatigue 
syndrome, but it may also appear  as an energy imbalance in daily living activities 
(Lerdal, et al., 2005).   
 
Pain                                                                                                                                                                      
Pain has been defined as “ an unpleasant sensory and emotional experience associated 
with actual or potential tissue damage, or described in terms of such 
damage”(Merskey, et al., 1994, p.210). The concept has a subjective implication, but 
limits it to a sensation that can be felt physically or emotionally because of tissue 
damage.  
Pain is in this way a biological response of tissue damage leading to a feeling that may 
be sharp, squeezing, cramping or burning. The intensity varies widely between 
individuals in verbal manifestations, with age, and cultural related issues (Lindsey, et 
al., 1993). The intensity of pain can  give other complications as sleep disruption 
(Merskey, et al., 1994).  Pain is known to be very distressing. Depression is also 
thought to be a pathology causing pain and distress (Lindsey, et al., 1993). Previous 
experiences may interfere with pain (Atkinson, et al., 1990). People, who have 
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previously suffered pain, may also have acquired strategies for mastering their 
discomfort. In this way previous experience may influence cognitive mechanisms of 
pain experience (Bandura, 1997).  Pain experience can also interfere socially in 
daytime activities. In COPD  the feeling of pain can be related to pain in the breast, 
and be explained by thorax and intercostals muscles (Rabe, et al., 2007) and associated 
with headaches with hypoxemia (Ozge, et al., 2006). 
 
2.4 Symptom model - Biopsychosocial approach 
 
Different frameworks have been developed to understand and study symptoms. The 
Middle-Range theory of unpleasant symptoms, The Symptom Experience Model,  The 
Symptom Interaction Framework and The Symptom Management Model are theories 
that have multiple symptoms interaction (Parker, et al., 2005), but with different goals 
(table 1). Below you will get an introduction to these multiple symptoms models and 
thereafter the chosen model will be presented in detail.      
 
Each model can be interpreted to have different components of a biospycosocial 
approach. George Engel introduced the biopsychosocial model in 1977                      
(Borrell-Carrio, et al., 2004). The biopsychosocial approach describes health as more 
than lack of illness. You have to see the relationship between the concepts 
psychological, sociological and biological situations in order to understand health 
(Borrell-Carrio, et al., 2004).  
 
Engel described the model as a linear cause-effect model                                                 
(Borrell-Carrio, et al., 2004;Engel, 1979).  There has been a lot of criticism of this 
model, but one in particular is that the clinical reality is more complex than the linear 
cause. There may be circular and structural causality (Borrell-Carrio, et al., 2004).                              
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The Middle-Range Theory of Unpleasant symptoms is an update of the theory of 
unpleasant symptoms. It shows a more interactive model than the current model which 
has been criticised to be linear. The model has a feedback loop from performance of 
the symptoms to influence of the symptoms, physiologically, psychologically and in 
situational factors. The theory explains and guides research of multiple symptoms. The 
model can seem to have a biopsychosocial function where 
Model Goal Factors that influence the symptoms 
The Middle-Range 
Theory of Unpleasant 
symptoms                              
An update of  The 
theory of unpleasant 
symptoms (Lenz, et al., 
1997). 
Presentation of the complexity 
and interactive nature of the 
symptoms experience. 
Physiological factors, psychological factors and situational factors 
influence the symptoms. Intensity distress, quality and duration are 
the characteristics of the symptoms. 
The Symptom 
Experience Model 
(Armstrong, 2003). 
Understand the meaning of the 
symptoms experience. 
Demographic characteristics, disease characteristics and individual 
characteristics are antecedents for the symptoms experience.  The 
symptoms experience is influenced by situational meaning and 
existential meaning.  The consequences are suggested to be: 
adjustment to illness, quality of life, mood, functional status, 
disease progression and survival. 
The symptom 
Interaction Framework                   
(Parker, et al., 2005). 
Increased understanding of the 
multidimensional mechanisms 
underlying symptom pairs and 
cluster. The main focus is to se the 
interaction cause of symptom. 
Biological domains, psychological domains, behavioural domains, 
sociocultural domains and a combination of mechanisms could 
explain symptoms experience and multiple symptoms.  
The symptom 
Management model   
(Dodd, et al., 2001a) 
To understand symptoms and use 
as a direction for interventions, 
informing research and help to see 
the association with variety of 
disease and conditions.  
 Symptoms experience, management strategies and outcomes are 
dimensions that are interrelated. Person variables, environment 
variables, health and illness variables are believed to influence 
these three dimensions. Person variables contain demographic, 
psychological, sociological, physiological and developmental 
characteristics.  
Table 1 -Multiple symptoms model 
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the biological factors derive from physiological factors, and the sociological factors 
are equivalent to situational factors (Lenz, et al., 1997).  The performance of the 
symptoms is described as the outcome variables. However, factors as for instance 
quality of life, morbidity, co-morbidity, self-care and economic state have not been 
described in the model as outcome variables. These factors may also be important in 
order to influence the symptom experience and they can be a result of experiencing the 
symptoms. 
 
The Symptom Experience Model aims for the subjectively perceived understanding of 
multiple symptoms. The experience of multiple symptoms can influence quality of 
life, functional state, psychological state, disease progression and survival (Armstrong, 
2003).   An interpretation of the theory describes factors involving biological domains 
(as disease characteristics), psychological domains (as mood, individual 
characteristics) and sociological domains (as demographic characteristics).                                                                              
The model may be criticized for showing a one way direction of the factors 
influencing multiple symptoms.  Furthermore it has not yet been tested out and it has 
been suggested to use a qualitative method for this approach (Barsevick, et al., 2006).  
 
The Symptom Interaction Framework tries to focus on bringing in the multi 
dimensional mechanisms underlying the symptoms. In other words the main goal is to 
see the interaction cause of the symptoms (Parker, et al., 2005). The theory is related 
to symptom pairs and clusters and symptom interaction. Physiological, psychological, 
behavioural and sociocultural mechanisms are described to underlie the symptoms. 
Environmental and developmental factors are in context of the symptom. All this gives 
a clinical outcome (Parker, et al., 2005).  The theory has not been tested out and 
interaction has not been defined. This may cause some confusion how to find the 
interaction.  
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2.4.1 The Symptom Management Model 
 
The choice of model in table1 depends on the aim of investigation. In this study the 
purpose is to investigate multiple symptoms and evaluate which predictors can 
interfere with the symptoms. These situations are complex and therefore we need a 
model which can present the complexity and interconnection between predictors and 
symptoms. The Symptom Management Model (SMM) (figure 1) has been chosen 
because:                                                                                                                                 
1. It illustrates and verbally describes important perspectives of the research questions 
in this thesis.                                                                                                                                    
2. The model shows that factors of biology, physiology, psychology and sociology can 
influence a person’s experience of symptoms.                                                                        
3. The model visualizes that symptoms are outcomes of multidimensional indicators 
more than in the other models reviewed above. The illustration of The Symptom 
Interactional Framework is for instance not as characteristic as in the SMM. Because 
of the visual illustration of SMM it immediately seems to give more information 
which makes it practical to use when planning a research project. This will be shown 
later in 4.3.                                                                                                                           
4. The SMM contains more information about factors such as quality of life and co-
morbidity than seen in the The Middle-Range Theory of Unpleasant symptoms. These 
factors are also believed to influence the symptom status (Dodd, et al., 2001a). It dose 
not have the linear construction found in The Symptom Experience Model. 
 
The SMM  has been developed on the basis of various research done in oncology 
patients (Dodd, et al., 2001a). It has not been tested out in many studies, but several 
studies have findings that are consistent with the theory. These papers have used the 
model to understand symptoms in angina (Caldwell, et al., 2000), HIV(Voss, et al., 
2006) and oncology (Dodd, et al., 2001b;Dodd, et al., 2001a).  
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Person variables, environment variables, health and illness variables are believed to influence symptom 
experience, symptom management strategies and the outcome of the symptoms 
 
Person domain contains variables that are important for an individual in order to 
discover and to respond to the symptom. These are demographic variables, 
psychological, sociological, physiological variables and developmental variables. 
These intrinsic variables may for instance be age and gender.                                                                                                 
 
Health Illness domain includes risk factors, health status, disease and injury. People 
with genetic asthma are more at risk than others to develop COPD when exposed to 
smoke (Barnes, 2008). This could have a direct or indirect effect on the three 
components of the model: symptom experience, management and outcomes.                                                                                 
 
Environment domain in the model is cultural aspects, physical environment like home 
and work and social environment like friends. Other relationships could interfere with 
the three components of the model (Dodd, et al., 2001a). An example of this could be 
the tradition in some cultures of cooking by open fire inside the houses. Thus people 
are more at risk to develop symptoms of COPD (ATS/ERS guidelines, 2004).  
 
 
Figure 1. -The symptom Management Model 
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Symptom experience is about a person’s ability to perceive, evaluate and respond to the 
symptom.                                                                                                                                   
The response to a symptom may be influenced by different causes. Being on sedative 
medication or being helped by a mechanical ventilator, a person with COPD could for 
instance fail to recognise the symptom breathlessness. Symptom experience, 
complexity of intensity, the location, the nature of the symptom, the frequency and the 
affective impact are factors that evaluate symptoms. Thus the response to the symptom 
influences the intensity of the symptom. The symptom experience dimension could be 
related to “illness perception”. The equal components imply how a person percepts 
and responds to illness (Broadbent, et al., 2006) and symptoms (Dodd, et al., 2001a). 
A theory like this one could be used to further investigate and understand the 
influences on symptoms in COPD. Illness perception  has been shown to be associated 
with coping strategies in COPD (Scharloo, et al., 1998).  
 
The component of symptoms management strategies includes assessment of the 
symptom from an individual perspective. This could be efficacy strategies. 
Specifications of efficacy could be: what symptom, when and where the symptom was 
experienced, why does the person feel this symptom and how much does he 
experience of the specific symptom (Dodd, et al., 2001a). How people believe that 
they will manage to take care of a symptom could be called their self-efficacy 
thoughts. This is described in Bandura’s self-efficacy theory (Bandura, 1977). For 
instance could a person with COPD get breathing difficulties when waiting for a bus at 
wintertime (many with COPD experience dyspnea when the weather is cold  (Silkoff, 
et al., 2005)) If the person can manage this situation well this may result in better 
efficacy next time he is in a similar situation. In this way peoples self-efficacy can 
influence how to manage a symptom like breathlessness. 
 
The outcomes variables emerge from symptom management and symptom experience. 
These outcome variables could be anxiety, depression, fatigue, insomnia, quality of 
life, mortality, co morbidity, functional state and the cost of being in need for 
economic finance from the health state/services (Dodd, et al., 2001a).                       
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These factors could also be influenced by each other.  In fact, several studies have 
found this. One symptom that is unrelieved could again influence other symptoms like 
in a cluster. The experience of variety of symptoms could also be associated with low 
score on quality of life (Dodd, et al., 2001a). These associations are also supported in 
Wilson & Cleary’s Quality of life model. Here it is suggested that a person’s 
characteristics and his environmental characteristic could influence biological 
variables, symptoms, function, general health and global quality of life. The biological 
variables could influence symptoms. Symptoms could in a two way interaction be 
associated with function, function with general health and general health with global 
quality of life (Osoba, 2007). 
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3. Studies  
 
3.1 Previous research in COPD 
 
The overviews of different symptoms in COPD studies are based on:                                      
1. Symptoms association with each other and lung function                                                    
2. That the different symptoms association with demographic variables. 
 
The number of papers illustrated in table 2 show the difficulties of getting a full 
picture of studies on symptoms in COPD. The literature search could have been done 
by limiting it to a period of years. However since some of the symptoms are well know 
(such as dyspnea) in COPD the relevant papers may be older than during the recent 
years.  Table 3 will therefore summarize some of the previous research and papers in 
COPD 
 
The search presented in table 2 and the papers presented in table 3 show that few 
studies have focused on more than three symptoms in COPD.  Most of the studies 
performed on three symptoms are done on the symptoms depression, anxiety and 
dyspnea. Depression and anxiety have often been objects of research in the same 
study.  This may be due to the close relationship of these two symptoms (2.3).  
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Illustration of search (words)  in Pub Med  (last search 14 of June 2008) 
Number of papers 
COPD dyspnea symptoms 
 
2115 
COPD dyspnea symptoms lung function 
 
1159 
COPD depression symptoms 
 
209 
COPD depression dyspnea symptoms lung function 
 
64 
COPD anxiety symptoms 
 
356 
COPD anxiety dyspnea symptoms lung function 
 
64 
COPD insomnia  
 
37 
COPD insomnia dyspnea symptoms lung function 
 
4 
COPD fatigue symptoms 
 
320 
COPD fatigue dyspnea symptoms lung function 
 
105 
COPD pain symptoms 
 
30 
COPD depression anxiety dyspnea symptoms lung function 
 
45 
COPD depression anxiety dyspnea fatigue sleep (not insomnia) 
 
4 
COPD depression anxiety dyspnea pain lung function symptoms 
 
2 
COPD depression anxiety dyspnea pain fatigue symptoms lung function 
 
1 
COPD depression anxiety dyspnea pain fatigue insomnia ( or sleep ) lung function  
Symptoms 
0 
 
 
 
Table 2. PubMed search result 
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3.2 Other studies on multiple symptoms 
 
As for other disabilities like Diabetes Mellitus (Hammer, et al., 2003) and 
Perimenstrual diseases (Taylor, 2005) there are examples of how multiple symptoms 
can be clustered. However most of the research done on multiple symptoms the recent 
years has been done in oncology (Dodd, et al., 2004).    
 
Fox et. al. explored the prevalence and intensity of depression, fatigue, and pain in 
survivors of lung cancer. Depression, fatigue and pain were found in the majority of 
the patients. Fatigue was the most intense symptom. The cluster explained 29% of the 
variance of quality of life in lung cancer (Fox, et al., 2006).  
 
Miaskowski et. al. investigated outpatients with cancer based on their experience on 
fatigue, sleep disturbance, depression and pain. Four subgroups were found. The 
subgroup reporting low level of all symptoms also reported best functional status and 
quality of life (Miaskowski, et al., 2006).                                                                                                               
These findings show how multiple symptoms in a complex way can have an impact on 
circumstances of in life.  Osoba has suggested that measuring multiple symptoms are 
important factors in measuring quality of life (Osoba, 2007). 
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4. Material and methods 
 
4.1 Setting 
This study was performed at an urban community hospital in Norway “Lovisenberg 
Diakonale Sykehus”. The hospital has 293 beds and is one of the largest private 
hospitals in Norway.  The hospital is one of four sector local hospitals in Oslo.  
Psychiatry, internal medicine and surgery are the main departments in the hospital. 
The area has a population of about 135 000 among which is an ethnic minority group 
(Lovisenberg Diakonale Sykehus, 2008) 
 
4.2 Design 
 
The study has a cross-sectional design. The participants filled out a booklet with 
demographic questions and standardized questionnaire tools (Appendix B). Lung 
function test, spirometry, was performed.  
 
4.2.1 Project: “Symptomcluster, self-efficacy and quality of life  for 
people who suffer from COPD” 
 
This thesis is part of a larger study: “Symptomcluster, self-efficacy and quality of life 
for people who suffer from COPD”. The symptom management model has been useful 
in designing the project.  In this study the following components of the Symptom 
Management Model have been covered by different standardised questionnaires: 
symptom experience, symptom management strategies and the outcome symptoms and 
quality of life.  Further the project patients have performed a 6 Minute walk test.  
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4.2.2 Analysis 
 
SPSS statistical package version 14.0 was used in the analysis.  Descriptive analysis 
by frequency mean and SD were used on demographic variables. Correlation analysis 
were used to detect association between the variables. A hierarchic multiple regression 
analysis was constructed in 3 steps. These steps were based on considerations in the 
research question.  The variables age, gender, education, smoking history, co-
morbidity (step 1), + predicted lung function (step 2) and + breathlessness (step 3) 
were put into the equation on each step.     
Statistic normality, linearity and homosecedasiticity were tested and satisfactory  
assumptions were met (Pallant, 2005). Each independent variable was regressed on all 
of the others and the level of  multi-collinearity (r>0.70) was acceptable (Pallant, 
2005). 
 
4.2.3 Sample size 
 
There are many variables included in this project. It is therefore difficult to calculate 
the sample size based on screening instruments. However, in the project “Symptom 
cluster, self-efficacy and quality of life for people who suffer from COPD” the plan is 
to identify symptomclusters and in this thesis to perform a multiple regression 
analysis. The sample size required is therefore based on these analyses. 
Symptomcluster analyses have not been done in COPD before, but according  to SPSS 
survival manual about 150 participants will be adequate (Pallant, 2005). The question 
of how many variables will be necessary in a multiple regression analysis is based on 
the principle of 10 persons per variable (Pallant, 2005). The multiple regression 
analysis in this thesis has 8 variables. On this background a number of 150 persons is 
adequate. 
 
4.2.4 Inclusion criteria 
The inclusion criteria were:                                                                                                     
- All stages of COPD diagnosed in the journal                                                                          
- Able to read and write Norwegian                                                                                       
- 30 years and older 
 
4.2.5 Data collection procedure 
 
On a list of 507 people with the diagnosis of (number) COPD, 392 matched the 
criteria to be included in the project. The patients were sent an invitation letter during 
the period June 2006-December 2007 (Appendix C). Sixty invitations were sent out 
every time (5 times). In the final round 92 invitations were sent out. After three 
weeks a reminder was sent to those who had not accepted. Among those who did not 
accept 31 people declined and 193 did not respond to the invitation. A total of 168 
accepted the invitation (Appendix D). Out of these two patients were not able to fill 
out the questionnaire, 6 patients withdrew the acceptance, 2 patients did not return the 
questionnaire and 4 patients did not meet for the appointment at the outpatient unit. 
154 (response rate 39%) of these participated in the project.                                                                          
The participants were phoned after having accepted.  An appointment was made for 
taking spirometry before and after a broncodilatator (Ventoline Accuhaler 0.2 mg x 
2). A letter with the appointment time and the questionnaire booklet was sent to the 
participants, which they filled out and brought back to the appointment with a 
respiratory nurse. It took about one to three weeks from the time the booklet was sent 
to the appointment at the hospital. Some of the participants cancelled their 
appointment with the major cause being due to an infection or an exacerbation. Then 
it took longer from the booklet was filled out until the appointment at the hospital. 
They were then asked to look over the questionnaire to see if there were questions 
they would answer differently. If there was a lot of questions they had not filled out, 
the respiratory nurse pointed them out and left the room for them to answer without 
interference. It took about 45 min to 1 ½ hours to fill out the questionnaire, but some 
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of the participants reported that they had needed 2 hours. At the appointment the 
project patients were able to ask questions about their COPD, medication and 
spirometry values. If necessary the respiratory doctor was contacted. Some of the 
patients needed extra treatment and were followed up at the outpatient unit by the 
respiratory doctor and the respiratory nurse. This was relevant if they could benefit 
from medication treatment or if respiratory failure was suspected and oxygen 
treatment would be needed. A note was written in their journal for those who required 
treatment. 
4.3 Instruments 
The parts of the symptom management model put to use in this project are illustrated 
in figure 2. Some of the variables can be interpreted to issues from several parts of 
the figure. In order to find the variables, lung function test spirometry, self-report of 
demographic questions and standardized questionnaires were carried out. 
 
Figure 2. – Illustration of variables put to use 
 
 
 
 
 
Co-morbidity and smoking  
Symptoms: breathlessness, anxiety, 
depression, fatigue, insomnia and pain 
 
Age, gender and education 
level and lung function   
 
Marital status and 
work 
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4.3.1 Spirometry measurement 
 
Spirometry is a test that measures physiological signs of how an individual inhales 
and exhales (Pellegrino, et al., 2005). The diagnosis COPD is identified by 
spirometry with the measurement of FEV1 (forced expiratory volume in one second) 
, FVC (forced vital capacity) and the ratio between these two measurements FEV% 
(FEV1/FVC) (Pellegrino, et al., 2005;ATS/ERS guidelines, 2004).                                                                     
A V-max spirometry was used for performing spirometry. This spirometer has 
Europeans reference values as standard.                                                                                  
All of the test participants performed the spirometry test in the way the “standard 
procedure of spirometry” test describes: “1) maximal inspiration; 2) a blast of 
exhalation; and 3) continued complete exhalations to the end of test”.                                    
A nose clip was attached and the lips of the patient were closed around the 
mouthpiece during the whole test procedure. The test was repeated for a minimum of 
three times. If the patient felt dizzy the test was stopped or not repeated. To be sure 
that the spirometer gave correct measurements it was calibrated with measured 
volume within ± 3,5 % using a 3-L syringe (Pellegrino, et al., 2005).  The participants 
were told not to inhale medication 4 hours before the test. This is a normal procedure 
to obtain spirometric values that are not influenced by medication, but also to be able 
to test medication effect (Pellegrino, et al., 2005). 
 
4.3.2 Measure of demographic variables 
Sociodemographic characteristic questions about gender, age, material status, 
education, employment, smoking status and living status were asked in the first part 
of the questionnaire booklet.   
4.3.3 Data from the medical record 
A separate worksheet used by the tester contained information about co-morbidity, 
how long they had been suffering from COPD and about medication. The information 
was found in the medical record. 
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4.3.4 Symptom measurement 
The second part of the questionnaire booklet contained a selection of instruments 
measuring the different symptoms (table 4). The instruments were selected on basis 
of other studies in COPD and multiple symptom research in oncology. It was 
important that questionnaires were considered relevant to the symptoms. Since we 
were supposed to investigate many variables it was important to choose instruments 
that were easy to use. Because few studies have focused on multiple symptoms in 
COPD  it was important to choose instruments of general nature. In this way it would 
be possible to compare with other populations. The author has asked permission to 
use the different questionnaires from those responsible for the tools in Norway.  
 
Unanswered questions                                                                                                         
Some of the participants had not answered all the questionnaires. These items were 
left unanswered when plotting this in SPSS. The same procedure was used for those 
who had answered two places in the same item. In order to calculate a sum score for 
the different symptom assessment scales respondents needed to answer 80 % of the 
items within each scale. As for the symptom pain this was not done due to the manual 
(Klepstad, et al., 2002).  
 
Reliability                                                                                                                               
To be sure of getting the relevant answer to the research question the tools used in 
this study must be reliable. Internal consistency using Cronbachs alpha is commented 
in each questionnaire. Cronbachs alpha involves estimating homogeneity between the 
different question on the same scale (Polit, et al., 2004). Questions that don’t belong 
to the issue can then disturb the internal consistency. Cronbachs alpha value goes 
from 0 to +1 (Polit, et al., 2004). A value above 0.7 as in this study is considered 
satisfactory (Pallant, 2005).   
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Validation                                                                                                                        
Instruments with rating scales have limitations caused by the person’s capacity to 
report, the characterization of the measurement and the boundaries imposed by the 
instrument. This may implicate the study and make the result of a study using 
instruments like this uncertain. Validation of the tool may give some insurance if the 
tool measures what it is suppose to do. 
 
RQLQ has only been used once in COPD. The construct validity was performed by 
comparing association between another health quality of life questionnaire. It was 
found to be highly correlated(Stavem, et al., 1999) 
 
GSDS has been validated among Chinese American parents with hospitalized infants. 
Concurrent validity was demonstrated and the instruments were found suitable to 
measure sleep among Chinese American population(Lee, 2007). It has been used in 
oncology, but not validated. However it had proved to bee useful in this group to 
measure sleep disturbance (Miaskowski, et al., 2006).                                                                                               
 
LFS has been tested in cancer patients. When comparing it with other fatigue 
instruments LFS has been supported to be valid (Meek, et al., 2000).                                                           
BPI was validated in oncology patients in Norway (Klepstad, et al., 2002). Because 
2-factors solutions were loaded together, 3-factors were found. This 3- factor model 
is pain intensity, interference with physical function and interference with 
psychological functions/sleep (Klepstad, et al., 2002).                                                                          
Because it seemed to be a tradition to use a 2- factor solution in several other studies 
this was used in the present study as well.                           
 
HADs has been used in several studies including COPD. Concurrent validity of 
HADS compared to other measuring tools has had various results, but conclusively it 
can be accepted as a good tool to assess symptoms of depression and anxiety 
(Bjelland, et al., 2002). 
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Questionnaires Subscale 
measure 
Question Translation and internal 
consistency 
Why used in this 
study 
Respiratory Quality 
of Life question-naire 
(RQLQ) (Stavem, et 
al., 1999;Marks, et 
al., 1992) 
Breathlessness, 
mood, concerns, 
and social   
Contains 20 questions 
scored on a 5 point scale.                      
Range score from 0-10 
(higher score more 
symptoms) 
Originally designed for 
studies in asthma. Translated 
in to Norwegian and used in 
COPD.                                              
In this study Cronbach’s 
alpha=0.85 (breathlessness 
score was used in this study) 
Few items and easy 
to use.  
Lee Fatigue Scale 
(LFS) (Miaskowski, 
et al., 1999;Gay, et 
al., 2004) 
Fatigue and 
energy 
Contains 18 questions 
scored on a scale from 0-10 
(higher score more 
symptoms).  
Used in oncology, and 
newborn babies and their 
parents. Translated to  
Norwegian.                                 
In this study Cronbach’s 
alpha =0.85 (fatigue score  
was used in this study) 
First time used in 
COPD in this study. 
It’s been proved to be 
easy to use and have 
a general nature. Can 
be compared with 
other populations.  
The Hospital Anxiety 
and Depression Scale 
(HAD) (Dowson, et 
al., 2001;Jones, et al., 
1992;Bjelland, et al., 
2002) 
Anxiety and 
Depression. 
Contains 14 questions. 7 
question on each subscale. 
Score range from 0-21 
(higher score more 
symptoms) 
Used in several diseases, 
included COPD. Translated 
to Norwegian.                                          
In this study Cronbach’s 
alpha= 0.86 for anxiety and 
=0.74 for depression. 
Easy to use, few 
items and there exists 
reference data from 
the Norwegian 
population. 
General Sleep 
Disturbance  Scale 
(GSDS) 
(Miaskowski, et al., 
2006;Gay, et al., 
2004;Lee, 2007) 
Insomnia  Contains 21 questions on a 
scale from 0-7 (higher score 
more symptoms).  
Used in oncology and for 
newborn babies and their 
parents. Translated to 
Norwegian.                                
In this study Cronbach’s 
alpha= 0.84  
First time used in 
COPD in this study. 
Easy to use and has a 
general nature. Can 
be compared with 
other populations 
Brief Pain Inventory 
(BPI)(Stenseth, et al., 
2007;Cleeland, et al., 
1994;Klepstad, et al., 
2002) 
Pain intensity 
and 
interference. 
The participants 
mark on a body 
map which part 
of the body they 
feel pain. 
Contains 14 questions. 11 of 
the questions have a rating 
scale from 0-10 (higher 
score more symptoms)                                
The body map was divided 
into 45 areas and counted by 
using a template. 
Used in oncology.              
Translated to Norwegian.               
In this study Cronbach’s 
alpha= 0.92 (pain 
interference score was used 
in this study) 
First time used in 
COPD in this study. 
It’s been proved to be 
easy to use and have 
a general nature. Can 
be compared with 
other populations. 
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5. Ethics 
 
The study was approved by the Medical Ethics Committee, the Data Inspectorate and 
the hospital clinic (Appendix E - G).                                                                                                                     
The selection of instruments to measure symptoms may lead to questions and 
emotional distress for the participants. Sensibly we therefore wanted the project 
patients to bring their booklets to the appointment.   
 
The fact that the participants performed the spirometry test at the hospital made it 
safe to participate. The tester always had a telephone available during the test, and 
could contact the respiratory doctor if needed. Some participants required further 
follow-up appointments and some also needed hospitalisation. The tester was 
certified in advanced cardiopulmonary resuscitation.  
 
The participants were given a number on the questionnaire, spirometry schedule and 
the separate work sheet.  The approval from the participants was marked with the 
same number. The sample of data from the participants and the sample of approval 
were stored in separate places to satisfy requirement of anonymity.   
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6. Discussion  
In the paper of this thesis the result of the present study is presented and discussed.  
The main findings show that breathlessness has the strongest association with all the 
other symptoms after controlling for demographic and clinical variables. 
Demographic variables, smoking, co-morbidity and lung function had different 
association with the different symptoms.                                                                                                                                   
As suggested by the Symptom Management Model these findings show that person 
variables, health & illness variables and environment variables influence multiple 
symptoms in various manners.                                                                                                     
The following section will contain a discussion and a reflection on theoretical 
background and methodological considerations around the significance and validity 
of these findings.  
 
6.1 Discussion of theoretical background 
Symptom definition                                                                                                             
Several definitions of the different concepts chosen in this study exist. Pain can for 
instance be defined as “whatever the experiencing person says it is, existing 
whenever he says it does”(Lindsey, et al., 1993, p. 235). The choice of definitions 
was difficult, because each definition would give a different approach. Maybe the 
definition of pain mentioned above would be better in a quality approach. As for the 
concept depression it was in literature often defined as a disease, even if the common 
expression would refer to a clinical symptom or to a general feeling. This can give an 
illustration of confusion of ideas which can make communication difficult. In this 
study a particular definition of the concepts has been chosen, but when the 
participants answer the questionnaire they may not have the same definition in mind. 
The only relationship between the definition and the patient then is if the 
questionnaire measures what the definition says. 
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Symptom model                                                                                                                          
The SMM was chosen because of the visual and verbal illustration of the complex 
circular understanding of symptoms. It has been useful in planning the project but 
also in evaluating the result afterwards. However we have not used the entire model 
and can therefore not give the complete picture of a “circular” understanding. The 
implied part only explains some of the associations, but other variables of the model 
could have a stronger impact on the outcome variable. With the variables we have in 
the multiple regression analysis the Theory of unpleasant symptoms may also be a 
model that could answer the research questions.  This model will however not give an 
understanding of the missing items such as quality of life. The entire model of the 
SMM could in this way give ideas of important factors to consider for further 
investigation.   
6.2 Discussion of methods 
 
6.2.1 Setting and sample 
 
Response rate and bias                                                                                                                                         
It can be considered as a strong point that the whole population of COPD patients 
from the outpatient list in a period was invited to participate in the study. In this way 
there will be a reduced effect of systematic bias.  However the response rate seemed 
to be low.  Polit and Beck state that a response rate of 50%  most typically achieved 
with mailed questionnaires, but with a face-to-face interview the response rate could 
be higher (Polit, et al., 2004). In this study the response rate was based on the mailed 
acceptation letter.  The participants also had a face-to-face meeting when performing 
the lung function test. The response rate of 40% in the present study may be due to 
the fact that “Lovisenberg Diakonale Sykehus” serves patients from various ethnic 
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minorities and patients with more severe disease may have hesitated to come all the 
way to the hospital only for the study 
The Medical Ethics Committee did not approve collecting data about minority 
background from the participants or the non-responders (Appendix H). Only names 
from the list of those patients not responding can to some extent suggest anything 
about origin. Also data on demographic characteristics such as gender and age can 
shed light on how representative the respondents are in relation to the population 
studied.  In order to document possible bias on non- responder’s analysis of age, 
gender and minority names were performed. The mean age of non- responders was 
67.7 with a SD of 12.4.  This differed only by 4.6% in age and 1.8% in SD compared 
to the participants in the study. The frequency of men and women were also similar to 
the participants. 48.4% were men and 51.6% were women in the sample of non-
responders. In the sample of participants 51.3% were men and 48.7% women. 
However there was an amount of 14.6% of people with names suggesting a minority- 
language in the sample of no-responders and this number was 6.4% in the 
participants.  
 
6.2.2 Design and analysis 
 
Design                                                                                                                                        
A Cross-sectional design was chosen because of the explorative focus of the project. 
Because this kind of design is known to be easy and relatively economical (Polit, et 
al., 2004) it was in the start of the project thought practicable to perform in a master 
thesis. Each participant had one hour appointment at the hospital to perform the 
pulmonary function test and talk to the respiratory nurse. Some of the participants 
needed an extra appointment for medical following up. Almost everyone wanted a 
journal note to be written and sent to their main doctor. Because of this, the study was 
more time consuming than expected. Most important, this design assured the 
participants that they would be taken care of if necessary. 
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The cross-sectional design will not estimate prediction of the direction of the 
variables.  The assumptions in this thesis are therefore to give some ideas of 
association but this should be further explored in forthcoming studies.  
 
Analysis                                                                                                                                
Other analysis methods could have been considered to analyse multiple symptoms. 
This could for instance be factor analysis, cluster analysis or pathway analysis. 
Methods as these would need other statistical programs than available in SPSS. 
However the result of using multiple regression analysis is a start that can give ideas 
for further studies on investigating multiple symptoms. Another approach such as 
simultaneous regression has been stated to be a commonly used multiple regression 
analysis (Pallant, 2005;Polit, et al., 2004). However, using a hierarchical multiple 
approach different steps of relationships may be explored. 
 
6.2.3 Instruments 
 
Performance of spirometry and reference values                                                                        
Spirometry instruments have reference values predicted by the normal population in 
their office program. Different reference values are used in different countries. In 
Norway the reference values from the European Respiratory Society are normally 
used as predicted spirometry values. Norwegian reference values exist, but they have 
been reported to be too high (Langhammer, et al., 2001). To consider accurate 
reference value is difficult and may also predict invariable data because a subjective 
consideration by the tester is needed for each patient.  Performing the test is also a 
technical procedure. This has proved to be difficult for several patients, probably due 
to insufficient understanding of the procedure (Ulmer, 2003). However, with trained 
technicians, and the spirometry test performed in the way illustrated by guidelines, 
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the test is mostly known as a good way to confirm diagnosis, evaluate disease and 
treatment (Schermer, et al., 2003). 
 
Use of questionnaires                                                                                                               
To an extent the validity of the instrument on other diseases could tell us if it was 
useful to measure the symptoms in COPD, but the disease could also be different 
from other conditions so the tools may not measure what they were intended to do.                                   
Some of the participants told the tester (author) that they had joined the project in 
order to measure their lung function and ask questions about their medications and 
their disease. Because of this they might not have been motivated to answer the 
questionnaires sincerely.                                                                                                        
In our sample some of the participants had a negative reaction to this questionnaire. 
Numerous questions were of a personal nature and may therefore have been difficult 
to answer truly.  
 
An evaluation of other questionnaires                                                                                 
Different measurement scales (such as VAS) and various questionnaires have been 
developed to measure breathlessness (Dorman, et al., 2007).  In this thesis the RQLQ 
subscale “breathlessness” was chosen.  Other questionnaires measuring dyspnea 
could also have been useful, but we preferred this questionnaire because it also 
measured additional conditions witch would be valuable in further analysis of the 
data. On the other hand other questionnaires, well known for information on cut 
points in different groups, could have been a better tool. Tools like the Medical 
Research Council Scale (MRC ) have been shown to give information that could help 
confirm the diagnosis of COPD and also grade the severity of the disease (Bestall, et 
al., 1999). This tool is used a lot and might possibly have been a better choice when 
evaluating this later.  
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6.3 Further research 
The studies give ideas for further investigation. In the expanded project other 
variables as for instance quality of life, self-efficacy and illness perception have been 
measured. The participants have also performed a 6 min. walking test with measuring 
of SpO2. Further analysis on this data could be to identify symptomclusters and find 
how these may be associated with illness variables such as lung function or SpO2 
during walking, self-efficacy and quality of life in COPD.  
 
The lack of connection between predicted lung function FEV1 and multiple 
symptoms in the present study and in other studies (3.1) raise questions as to why 
guidelines still focus so much on these signs in diagnosing and helping people with 
COPD. The author has not found any study investigating if psychosocial issues are 
points that are discussed with COPD patients during consultations. Using 
questionnaires this study and several other studies have found people with COPD 
suffering from symptoms. Could questionnaires for instance be used in clinical 
meetings between the care worker and the patients in order to approach psychosocial 
issues? A project with standardized questionnaires in clinical practice might enable 
bringing these issues into a conversation with COPD patients.  
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7. Conclusion  
This is the first study to focus on multiple symptoms such as breathlessness, 
depression, anxiety, fatigue, insomnia and pain. Few studies focus on multiple 
symptoms.  
The findings of this study are presented in the paper.  These findings showed that 
breathlessness had the strongest relationship with all the symptoms after controlling 
for demographic and clinical variables. Among the different symptoms breathlessness 
and insomnia were the only symptoms to be related to predicted lung function.  
Significant relationships were also found between demographic variables, smoking, 
co-morbidity and the different symptoms. The theoretical framework The Symptom 
Management Model proved useful in planning, accomplishing and evaluating the 
result of the present study.                                                                                                                                       
The response rate seemed to be low, but this could be due to the population originally 
invited to participate in the project.  However, this result may be of valuable 
information for further investigation. The results from this study may suggest an 
expanded focus on multiple symptoms in COPD guidelines, health care and research. 
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Abstract 
Aim: The aim of this study was to explore the relationships between demographic and clinical 
variables, and multiple symptoms such as breathlessness, depression, anxiety, fatigue, 
insomnia and pain in COPD.  
Background: Although research in COPD often has focused on single symptoms there is a 
lack of knowledge about possible associations with multiple symptoms.  
Methods: A total of 154 COPD patients participated in a cross-sectional study from June 
2006 to December 2007.  All performed pulmonary lung function tests and completed a 
questionnaire that included demographic variables, Brief Pain Inventory, Hospital Anxiety 
and Depression Scale, Lee Fatigue Scale, General Sleep Disturbance Scale and Respiratory 
Quality of Life Questionnaire. Co-morbidity and medication were collected from their 
medical records. The following analysis method was used: descriptive, bivariate correlation 
and multiple regression analysis.  
Results:  With regard to demographic variables, age was significantly related to 
breathlessness, fatigue, insomnia and pain. Education was significantly related to depression 
and anxiety. Smoking was significantly related to anxiety, depression and pain. Co-morbidity 
was significantly related to breathlessness. 
Bivariate relationships showed that breathlessness, depression, anxiety, fatigue, insomnia and 
pain were significantly related to each other. In the multiple regression analysis, lung function 
was related to breathlessness and insomnia. Breathlessness was the most significant symptom 
associated with the other symptoms after controlling for demographic and clinical variables. 
 Conclusion: Breathlessness is a significant symptom associated with depression, anxiety, 
fatigue, insomnia and pain. Results from this study may suggest an expanded focus on 
multiple symptoms in COPD guidelines, health care and research. 
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Summary statement 
What is already known about this topic: 
• Breathlessness is a major symptom in COPD. 
• Predicted lung function signs are often found associated with breathlessness, but not 
with other symptoms. 
• Research on symptoms in COPD is explored within the scope of single symptoms 
such as breathlessness, depression, anxiety, insomnia and fatigue. 
 
What this paper adds: 
• This is the first study which explores multiple symptoms such as breathlessness, 
depression, anxiety, fatigue, insomnia and pain in COPD, using The Symptom 
Management Model. 
• Breathlessness has a strong significant association with symptoms such as depression, 
anxiety, fatigue, insomnia and pain after controlling for demographic and clinical 
variables. 
• Further studies of multiple symptoms in COPD are needed to guide symptom 
management. 
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Introduction 
Chronic Obstructive Lung Disease (COPD) is a serious chronic disease characterized by 
airflow limitation that is not fully reversible. About 80 million people in the world suffer from 
severe COPD which often leads to hospitalization and mortality (Hurd, 2000;ATS/ERS 
guidelines, 2004).  
In COPD patients, breathlessness is a major symptom. Although separate studies have 
reported that single symptoms such as depression, anxiety, fatigue, insomnia and pain are 
present (Kellner, et al., 1992;Theander, et al., 2004;George, et al., 2003;Mahler, et al., 1995), 
no study has focused on multiple symptoms in one and the same study. 
 
Background 
 The concept symptom can be understood as the subjective experience of a biopsychosocial 
change in the body (Dodd, et al., 2001a).  Multiple is defined as “more than one” (Webster 
dictionary, 1983). Multiple symptoms can in this way be understood as more than one 
symptom. Understanding symptoms in a more complex perspective is of great importance in 
exploring the need for the health care of COPD patients.  
The Symptom Management Model (SMM)(Dodd, et al., 2001a) is a conceptual framework 
resulting from research on oncology patients (Dodd, et al., 2001b). It has also been used to 
assess symptoms for HIV(Voss, et al., 2006) and angina (Caldwell, et al., 2000). However it 
has never been used to understand symptoms in COPD patients. The model has three 
interrelated dimensions; symptoms experience, management strategies and symptom 
outcomes. Personal, environmental, health and illness variables are believed to influence these 
three dimensions (Dodd, et al., 2001a). Several studies on oncology patients have suggested 
how multiple symptoms can appear concurrently and how different variables can interfere, 
such as social variables like education, personal variables like gender and  health & illness 
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variables like treatment (Miaskowski, et al., 2004;Miaskowski, et al., 2006;Miaskowski, et al., 
2006).  
We know that the relationship between respiratory signs such as FEV1% and different 
symptoms is not linear in COPD (Larson, et al., 2006). Breathlessness has shown an 
association with the predicted lung function FEV1% (Mishima, et al., 1996;Mahler, et al., 
1992). Anxiety and depression are associated with dyspnea , but not with FEV1 % (Mishima, 
et al., 1996;Gift, 1990). Kapella et.al found the same situation with the symptoms of fatigue 
and insomnia (Kapella, et al., 2006). Despite this situation the focus in guidelines for COPD 
is mostly on respiratory signs such as FEV1% and on symptoms such as breathlessness, 
sputum and cough (ATS/ERS guidelines, 2004).  Other factors like gender and co-morbidity, 
education and smoking history (Hynninen, et al., 2007;Chavannes, et al., 2005;Lin, et al., 
2005;ATS/ERS guidelines, 2004) have shown to be related to symptoms in COPD patients. 
However, no study has examined possible relationships between selected demographic and 
clinical variables in relation to multiple symptoms in COPD. Considering the burden of 
symptoms for COPD patients and the increasing incidence of this disease (Hurd, 2000) it is 
important to expand our knowledge about multiple symptoms and the factors that could 
influence multiple symptoms.  
 
The Study  
The present study aims to answer the following questions:  
1. What is the relationship between the demographic variables smoking, co-morbidity and 
lung function, and multiple symptoms (breathlessness, depression, anxiety, insomnia, fatigue 
and pain)? 
2. What is the relationship between breathlessness and depression, anxiety, insomnia, fatigue 
and pain, controlling for demographic and clinical variables? 
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Design  
This paper is based on data from a cross-sectional study in COPD.  The patients were 
registered at an outpatient unit list at a medium-large hospital in Norway during the period 
from June 2005- May 2006. The participants answered a questionnaire booklet and came to 
an appointment at the hospital to perform a lung function test spirometry. It took about one to 
three weeks from the time that the booklet was sent until the appointment.  
 
Sample 
The following inclusion criteria were used to identify suitable respondents: all stages of 
COPD diagnosed in the medical record, able to read and write Norwegian and more than 30 
years old. Out of 502 COPD patients, 387 patients fulfilled the inclusion criteria and were 
invited to participate in the study during the period from June 2006-December 2007. After 
three weeks a reminder was sent to those who had not responded. A total of 168 accepted the 
invitation. Out of these, two patients were not able to fill out the questionnaire, six patients 
withdrew their acceptance, two patients did not return the questionnaire and four patients did 
not meet up to the appointment. A total of 154 persons (response rate 40%) participated in the 
study.  
See figure 1 for further information.  
 
Figure 1 about here 
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Data Collection 
Physical tests 
 Lung function values were measured before and after the inhalation of Salbutamol (0.4 mg). 
The participants were told not to take inhalation medication less than four hours before the 
lung function test spirometry (V-Max spirometry with European standard measurement). All 
the tests were performed in accordance with American Thoracic Society (ATS)/ European 
Respiratory Society (ERS) standardization for lung function testing (Pellegrino, et al., 2005).   
   
Instruments and scoring procedure 
The test instruments for the study included a questionnaire booklet with information on 
sociodemographic characteristics (gender, age, marital status, education, employment, 
smoking status and living status) and standardized instruments used in previous studies. 
Information about co-morbidity and medication was collected from the medical record.  
 
Respiratory Quality of Life questionnaire (RQLQ) measures quality of life specific to COPD.  
This instrument was originally made and used in studies of asthma patients in Australia 
(Marks, et al., 1997;Marks, et al., 1992).  It has been translated into Norwegian and used in 
COPD (Stavem, et al., 1999). It contains 20 questions with a range score from 0-10.  A higher 
score indicates a higher intensity of breathlessness. Each item has a five point scale: “not at 
all, mildly, moderately, severely and very severely”. It has four subscales: breathlessness, 
mood, concerns and social. This study concentrates only on the subscale breathlessness. 
RQLQ has shown satisfactory internal consistency in previous research (Stavem, et al., 1999). 
In this sample the Cronbach’s alpha was 0.87 for the subscale breathlessness. 
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Lee Fatigue Scale (LFS) was used to measure fatigue. It consists of 18 questions with a range 
score from 0 to 10.  A higher score indicates higher intensity of fatigue. Thirteen of the 
questions contain information about the feeling of fatigue. Five questions contain information 
about energy. Only the fatigue score was used in this study. LFS has not been used in COPD 
patients but was still chosen because of its general nature. Because the LFS contains questions 
not directly related to the disease it is possible to compare to other populations and diseases.            
This instrument has been used in oncology studies (Miaskowski, et al., 2006;Miaskowski, et 
al., 1999) and with newborn babies and their parents (Gay, et al., 2004b). LFS has shown a 
satisfactory internal consistency in previous research (Dowson, et al., 2001). In this study the 
Cronbach’s alpha was 0.85 for the subscale fatigue. 
 
Brief Pain Inventory (BPI) was used to measure pain, and consists of four questions related to 
pain intensity with a rating scale from 0 (no pain) to 10 (excruciating).  It also contains seven 
questions related to pain interference with a rating scale from 0 (does not interfere) to 10 
(completely interferes). The score ranges from 0-40 for pain intensity and from 0-70 for pain 
interference. A high score indicates more severe pain.  The participants were asked to mark 
with a pencil /pen on a body map on which part of their body they experienced pain.  The 
procedure used by Rustoen et. al. was performed to score the marked areas of pain on the 
body map (Rustoen, et al., 2004).  The body map was divided into 45 areas, and each area 
was scored and counted by using a template. BPI has been used in oncology (Stenseth, et al., 
2007;Cleeland, et al., 1994) and translated into Norwegian (Klepstad, et al., 2002). The pain 
interference subscale was used in this study. BPI has shown satisfactory internal consistency 
in previous studies (Klepstad, et al., 2002;Paul, et al., 2005). In this study Cronbach’s alpha 
was 0.92 for the subscale pain interference. 
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The Hospital Anxiety and Depression Scale (HAD) has been used to measure anxiety and 
depression. It contains 14 items. Each question has a four point scale where seven items on 
each subscale measure anxiety and depression. The scale ranges from 0-21, with higher scores 
indicating the presence of anxiety and depression. HAD has been translated into Norwegian 
and has been used for different disease groups, including COPD (Dowson, et al., 2001;Jones, 
et al., 1992). HAD has shown satisfactory internal consistency in previous studies (Bjelland, 
et al., 2002). In this study Cronbach’s alpha was 0.86 for the subscale anxiety and 0.74 for the 
subscale depression. 
 
General Sleep Disturbance Scale (GSDS) was used to measure insomnia. The questionnaire 
includes 21 items with a range from 0-7 (how many days per week). The scale ranges from 0-
147.  A higher score indicates a higher degree of sleeping problems. This instrument has been 
used in oncology research (Miaskowski, et al., 2006) and for measuring the pattern of 
sleep/fatigue with newborn babies and their parents (Gay, et al., 2004a;Gay, et al., 2004a;Gay, 
et al., 2004b). The questionnaire has been translated into Norwegian. In previous studies the 
GDSD has shown a satisfactory internal consistency (Lee, 2007;Gay, et al., 2004a).  In this 
study Cronbach’s alpha was 0.84 for the subscale insomnia. 
 
Ethical considerations 
The study was approved by the Medical Ethics Committee, the Data Inspectorate and the 
hospital clinic. The invitation letter contained information about the project and anonymity 
procedures regarding the participants.  
  
 
 
 71 
Data analysis 
The statistical analyses were performed using the SPSS statistical package version 14.0.  
Demographic variables and the severity of various symptoms and lung function were 
analyzed with descriptive analyses (frequency, mean, SD). Analyses of the relationships 
between lung function, demographic characteristics and the symptoms were performed using 
bivariate correlation analysis (Pearson’s r) and by hierarchic multiple regression analysis 
(enter method). The hierarchic multiple regression analyses followed three steps:  
Step 1:  
Independent variables: Age, gender, education, smoking history and co-morbidity. 
Dependent variables: Breathlessness, depression, anxiety, insomnia, fatigue and pain. 
Step 2:  
Independent variables: Age, gender education, smoking history, co-morbidity + predicted 
lung function FEV1%. 
Dependent variables: Breathlessness, depression, anxiety, insomnia, fatigue and pain. 
Step 3:  
Independent variables: Age, gender, education, smoking history, co-morbidity, predicted lung 
function FEV1% + breathlessness. 
Dependent variables: Depression, anxiety, insomnia, fatigue and pain. 
 
Statistic normality, linearity and homosecedasiticity were tested and satisfactory  assumptions 
were met (Pallant, 2005). Each independent variable was regressed on all of the others and the 
level of  multi-collinearity (r>0.70) was acceptable (Pallant, 2005). 
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Results   
Demographic characteristics, smoking history, co-morbidity and location of pain 
The demographic characteristics are shown in table 1. Out of 154 participants 51.3% are men 
and 48.7% are women. The age range is from 36 to 87, with a mean age of 64.6 years. A total 
of 44.2% are non smokers and 43.5% are still in the habit of smoking.  A total of 18.1% have 
a university education of less than four years, and 9.7% have more than four years. The rest of 
the participants have attended primary school, vocational school or secondary school.  Many 
of the participants have several diseases. Among these 39% have low or high blood pressure, 
31.2% have heart disorders, 22.1% have joint disorders, 16.9% have stomach and kidney 
disorders and 11.7% have diabetes. A total of 18.8% have no other disorders.  The body map 
shows that 33% mark pain in the shoulders, 29.2% in the lumbar region, 26.6% in the legs, 
21.4% in the back, 16.9% in the neck, 16.2% in the thighs and 12.3% in the head. 
With regard to the non-respondents the mean age is 67.7 years and 14.6% have a minority 
background. The relative proportion of men and women is similar between the group of 
participants and the group of non-participants.  
 
Table 1 about here 
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Characteristics of lung function and symptoms 
Descriptive information on variables such as lung function, symptoms, and the Gobal 
Initiative for Chronic Obstructive Lung Disease (GOLD) classification of the severity of 
COPD (Rabe, et al., 2007) is presented in table 2.  
 
Table 2 about here 
 
The relationship between demographic variables, smoking, co-morbidity, lung function 
and multiple symptoms 
Table 3 presents the results of the bivariate analysis (Pearson’s r, column r) and the 
multivariate linear regression analyses of the relationships between independent variables 
(demographic variables, smoking, co-morbidity and lung function) and multiple symptoms as 
dependent variables.  
The bivariate analyses show that breathlessness is significantly negatively related to age 
(p<0.05, r=-0.19), education (p<0.01, r=-0.23) and lung function (p<0.01, r=-0.36) and 
positively related to co-morbidity (p<0.05, r=0.16). In the multivariate analysis only age 
(p<0.01, st.beta = -0.22) and lung function (p<0.01, st.beta =-0.34) are significantly related to 
breathlessness (step 2, table 3).  
As for depression (p<0.01, r=-0.24) and anxiety (p<0.01, r=-0.26), the bivariate relationship 
shows a significant negative relationship with education. Education stays significant (p<0.05, 
st.beta =-0.2) in the model after controlling for the independent variables (step 2, table 3). 
However, smoking is negatively significantly related to anxiety (p<0.05, st.beta =-0.17) and 
depression (p<0.05, st.beta =-0.17) (step 2, table 3). 
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No bivariate associations are found for the separate independent variables and fatigue. 
However age is negatively significantly related to fatigue (p<0.05, st.beta =-0.17) at the 
second step (step 2, table 3) in the multivariate analysis. 
The bivariate relationship also shows that age is negatively related to insomnia (p<0.01, r=-
0.25). After controlling for independent variables, age stays negatively significantly related to 
insomnia (p<0.01, st.beta =-0.23) at the second step (step 2, table 3).  
Pain interference is negatively significantly related to age (p<0.01, r=-0.24), smoking 
(p<0.01, r=-0.21) and positively related to gender (p<0.05, r=0.17). Age (p<0.05,                     
st.beta =-0.19) and smoking (p<0.05, st.beta =-0.2) remain significantly associated to pain 
interference when independent variables are controlled for at the second step (step 2, table 3) 
in the multivariate analysis.   
The variance explained within all the models shows a range from 2%-10% at step 1 (table 3) 
and a range from 1% to 10% at step 2 (table 3). 
 
Table 3 about here 
 
The relationships between breathlessness and depression, anxiety, insomnia, fatigue and 
pain, controlling for demographic and clinical variables 
Table 4 shows a significant positive (p<0.01) bivariate relationship between all the symptoms. 
The Pearson r ranges between 0.3 (fatigue-depression) and 0.61 (insomnia-pain interference). 
Breathlessness is negatively significantly related to lung function  (p<0.01, r=-0.36).  
 
Table 4 about here 
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When controlling for demographic and clinical variables, breathlessness is significantly 
positively related to depression (p<0.01, st.beta =0.34) and anxiety (p<0.01, st.beta =0.34), 
fatigue (p<0.01, st.beta =0.39), insomnia (p<0.01, st.beta =0.45) and pain interference 
(p<0.01, st.beta =0.43) (step 3, table 3). However, lung function is positively significantly 
related to insomnia (p<0.05, st.beta =0.22) after breathlessness entered the equation at the 
third step (step 3, table 3).  
The Adj.R Square for fatigue is 13%, for anxiety 14%, for depression 15%, for insomnia 22% 
and for pain interference 25%. 
 
Discussion  
To our knowledge this project is the first which in one single study includes multiple 
symptoms such as breathlessness, depression, anxiety, fatigue, insomnia and pain in COPD, 
and tries to explore the relationships between selected demographic and clinical variables and 
multiple symptoms. 
 
Our main findings showed that breathlessness had the strongest relationship with all 
symptoms after controlling for demographic and clinical variables. The various symptoms had 
a different, significant relationship with demographic variables, smoking, education, co-
morbidity and lung function.  In accordance with the Symptom Management Model these 
findings support that personal variables, health & illness and environmental factors influence 
multiple symptoms in various manners.     
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Study limitations 
The study reported on in this paper may have limitations such as a low response rate and the 
cross-sectional design. The low response rate (40%) may be due to the fact that the 
participants were invited by letter and patients with more severe disease of COPD may have 
hesitated to come all the way to the hospital only for the study. Several of the non-participants 
also had a minority background. Because of the cross-sectional nature of this study it is not 
possible to draw conclusions about predictive issues with regard to the relationships found in 
this study.   
 
Severity of the various symptoms                                             
The five symptoms that are reported commonly in COPD were selected for this analysis. Pain 
interference has however not been previously investigated in COPD. Because of this, it is 
surprising that the mean score of pain interference in the present study is similar to the mean 
score in oncology patients (Klepstad, et al., 2002;Stenseth, et al., 2007). Although fatigue has 
been found to be a highly relevant symptom in COPD (Kapella, et al., 2006), the instrument 
used in the present study will make it possible to compare with other diseases. In the present 
study, the mean score of fatigue and insomnia was  found to be similar to the baseline mean 
score values for male patients with prostate cancer(Miaskowski, et al., 2008) and baselines 
mean score values of bone metastasis patients(Miaskowski, et al., 1999) before  treatment.  As 
for depression and anxiety symptoms, the mean score was similar to other studies of COPD 
patients getting oxygen therapy (Mishima, et al., 1996).  The mean score of breathlessness 
seemed to be not as high as the mean score Stavem et. al. found with the same breathlessness 
score (Stavem, et al., 1999).  There is however significant uncertainty about how large this 
difference is. We recommend that further research is conducted to validate the measure of 
breathlessness with RQLQ. 
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The relationship between demographic variables, smoking, co-morbidity and lung 
function and multiple symptoms 
Our results suggest that younger people experience more breathlessness, fatigue, insomnia 
and pain interference. Reishtein also found a negative correlation between age and the 
symptoms dyspnea and sleep difficulties (Reishtein, 2005), but other studies have reported 
increased insomnia (Klinkenberg, et al., 2004) and breathing problems with higher age 
(Hardie, et al., 2005). A study of pain in the Norwegian population showed that the proportion 
of pain was larger for older people (Rustoen, et al., 2004). Bandura explains aging as an 
exercise of control.  From this perspective getting older will give experience in controlling the 
symptoms or the biopsychosocial changes in the life of several people (Bandura, 1997). In 
order to investigate this further one may include components such as “self-efficacy” (Dodd, et 
al., 2001a). 
 
More women than men are associated with pain interference in the present study.   Because 
many studies have shown a difference between men and women when it comes to the 
experience of different symptoms, it is surprising that we don’t find any association between 
gender and the other symptoms. For instance Di Marco et. al found that women experienced 
significantly more anxiety and depression than men (Di, et al., 2006). A Norwegian 
population study showed that women had a higher fatigue score than men (Loge, et al., 1998). 
Kapella et.al. found a different score for sleep quality and fatigue between men and women 
but not with anxiety and depression (Kapella, et al., 2006). 
 
In our study, lower education is connected with a higher score of depression, anxiety and 
breathlessness and this is  supported by Van Manens et. al. study. They found that the 
majority of people with COPD  had lower education (van Manen, et al., 2001).   
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Our result shows that smoking status is related to depression, anxiety and pain interference. 
This is supported by others as well. Smoking has been found to have a relationship with 
depression in the general population in Norway (Klungsoyr, et al., 2006). Some people with 
anxiety symptoms also tend to use cigarettes as anxiolytic effect (Mikkelsen, et al., 2004). As 
for pain, it has been reported that people with musculoskeletal pain tend to smoke more. 
(McBeth, et al., 2007).  
 
Because many of the participants had co-morbidity, one could expect that the relationship 
between co-morbidity and symptoms would be more pronounced. Van Manen et.al found that 
pain was influenced by co-morbidity in COPD patients (van Manen, et al., 2003). Walke et. al 
found the opposite, the amount of co-morbidity showed a non- significant relationship with 
the severity of symptoms anxiety, depression and pain in COPD (Walke, et al., 2007).   
 
As in our study, several studies have also found low lung function to be associated with 
increased breathlessness (Mishima, et al., 1996;Mahler, et al., 1992). Our findings suggested 
that lung function and age have a more pronounced influence on breathlessness than on the 
other symptoms. This was also shown through no significant associations between lung 
function and the other symptoms; depression, anxiety, fatigue, insomnia and pain 
interference. Other studies have found similar results (Mishima, et al., 1996;Mahler, et al., 
1992;Gift, 1990;Kapella, et al., 2006). In spite of this it has been stated that people with 
severe to very severe COPD (lung function FEV1%<50%) can have a high feeling of 
depression (van Manen, et al., 2002). In our study we focused on all stages of COPD, and the 
fact that the results showed no connection between lung function and depression may be seen 
in light of this. 
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The relationship between breathlessness and depression, anxiety, insomnia, fatigue and 
pain, controlling for demographic and clinical variables  
In this study we have shown that breathlessness is related to all of the symptoms after 
controlling for demographic and clinical variables. 
 
Because few studies of COPD focus on the symptom pain, it is interesting that breathlessness 
explained the ultimate variance of pain interference in our study. Pain is however complex 
and may be caused by many different changes in the body (Lindsey, et al., 1993).  Özge et. al. 
suggested for instance that chronic hypoxemia and associated sleep disorder can be the reason 
for headaches of a severe to a very severe degree in COPD (Ozge, et al., 2006). Also 
discomfort in legs during activity and distress in breathing muscles are common in COPD. 
This condition may be due to changes in the chest wall, diaphragm position, overloading of 
respiratory muscles or oxidative stress in muscles (MacIntyre, 2006;Orozco-Levi, 2003). Our 
study reports that most of the pain was situated in shoulders, back, lumbar region, legs and 
thighs. These factors may explain the variance of pain in association with breathlessness. 
However it might be necessary to do further investigations of the symptom pain in order to 
clarify the interrelationship between pain and other factors in COPD.  
 
Breathlessness does not explain the total variance of insomnia in our study. The positive 
association with lung function can indicate that people with good lung function have more 
symptoms of insomnia. These results conflict with earlier findings of chronic airflow 
limitation contributing to sleep disruption (George, et al., 2003). It is well known that 
inhalation medication as beta 2 stimulating and corticosteroids used twice a day by many  
COPD patients can interrupt sleep (George, et al., 2003). These medications can also give a 
better lung function (ATS/ERS guidelines, 2004). This may be the reason for our results. 
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 Several studies suggest that anxiety and depression are associated with breathing difficulties 
(Bailey, 2004;Kellner, et al., 1992). The reason why anxiety and depression are related to 
breathlessness is complex. Anxiety is often related to panic and fear and can therefore cause 
breathlessness which again brings on more anxiety (Bailey, 2004). Feelings of hopelessness 
because of limitations and lack of energy (Sirey, et al., 2007) in activities such as shopping 
and cleaning can also develop depression. The feeling of anxiety and depression often results 
in social isolation, loneliness, helplessness and hopelessness(Kara, et al., 2004). Depression 
and anxiety can in this way seem to overlap each other (Mikkelsen, et al., 2004). The high 
correlation between anxiety and depression, and the same explaining variance of 
breathlessness associated with anxiety and depression shown in our study may explain this.   
 
As with depression and anxiety, fatigue also has smaller explaining variance than insomnia 
and pain interference. This result is quite surprising since other studies have found dyspnea to 
be highly related to fatigue (Kinsman, et al., 1983). Dyspnea was also related to anxiety, 
helplessness and hopelessness in this study (Kinsman, et al., 1983). Kapella et.al 
demonstrated in a study that dyspnea and fatigue were the most prominent symptoms of 
disability in functional performance. In their study, other symptoms such as anxiety, 
depression and sleep quality were also predictors to functioning (Kapella, et al., 2006). 
Fatigue has also been found to be quite common for those with sleeping difficulties in COPD 
(Mohsenin, 2005). These studies demonstrate how multiple symptoms can be associated with 
each other. We can find these associations by bivarite correlation between all of the 
symptoms. Further analyses are needed to gain more knowledge about multiple symptoms 
associations with each other. 
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Clinical implications 
ATS/ERS guidelines recommend the use of spirometry to measure the severity and set the 
diagnosis in COPD. However there are few suggestions to be found about how to investigate  
and help symptoms such as depression, anxiety, fatigue, insomnia and pain (ATS/ERS 
guidelines, 2004).  This view is supported by others as well (Walke, et al., 2007). Vestbo et. al 
questioned whether measuring breathlessness was a better tool to classify severity than lung 
function (Vestbo, et al., 1988).  Schlecht et. al suggest dyspnea measuring as a better method 
of reflecting both function and psychological impact in COPD (Schlecht, et al., 2005). Our 
results support this view and more focus on multiple symptoms in guidelines and health care 
is suggested.  
  
Conclusion and further research 
Our main findings showed that breathlessness had the strongest relationship with all 
symptoms after controlling for demographic and clinical variables. The various symptoms had 
a different, significant relationship with demographic variables, smoking, education, co-
morbidity and lung function. This analysis can contribute to investigating how symptoms are 
associated with each other in clusters (three or more symptoms associated with each other 
through a common mechanism or etiology through a shared common variance (Miaskowski, 
et al., 2007). Symptom cluster (of fatigue, sleep disturbance, depression and pain) show an 
association with the low quality of life of patients with cancer. This kind of association may 
also be found in COPD. Further research should explore the relationship between several 
symptoms by looking into symptom cluster analysis to understand more about what kind of 
predictors can be influenced. 
 
 
 82 
Acknowledgments 
The authors would like to thank Lovisenberg Diakonale Sykehus for making it possible to 
perform this project. 
 
Author contributions 
C. R. Borge and A. K. Wahl were responsible for the study conception, design and analysis.            
C. Miakowski provided guidance on the concept.  C. R. Borge performed the data collection 
and was responsible for drafting the manuscript. A. K. Wahl and C. Miakowski supervised the 
content of the paper. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 83 
Reference List 
 
ATS/ERS guidelines.  American Thoracic Society. European Respiratory Society. 
Standards for the Diagnosis and Management of Patients with COPD.  2004.  
Ref Type: Report 
Bailey, P. H. (2004). The dyspnea-anxiety-dyspnea cycle--COPD patients' stories 
of breathlessness: "It's scary /when you can't breathe" 
5.Qualitative Health Research, 14, 760-778. 
Ref Type: Journal 
Bandura, A. (1997). Self-efficacy 
the exercise of control. New York: Freeman. 
Ref Type: Book, Whole 
Bjelland, I., Dahl, A. A., Haug, T. T., & Neckelmann, D. (2002). The validity of 
the Hospital Anxiety and Depression Scale. An updated literature review 
1.Journal of Psychosomatic Research, 52, 69-77. 
Ref Type: Journal 
Caldwell, M. A. & Miaskowski, C. (2000). The symptom experience of angina in 
women.Pain Manag.Nurs., 1, 69-78. 
Ref Type: Journal 
Chavannes, N. H., Huibers, M. J., Schermer, T. R., Hendriks, A., van, W. C., 
Wouters, E. F., & van Schayck, C. P. (2005). Associations of depressive symptoms with 
gender, body mass index and dyspnea in primary care COPD patients.Family Practice, 
22, 604-607. 
Ref Type: Journal 
Cleeland, C. S., Gonin, R., Hatfield, A. K., Edmonson, J. H., Blum, R. H., 
Stewart, J. A., & Pandya, K. J. (1994). Pain and its treatment in outpatients with 
metastatic cancer.New England Journal of Medicine, 330, 592-596. 
Ref Type: Journal 
Di, M. F., Verga, M., Reggente, M., Maria, C. F., Santus, P., Blasi, F., Allegra, L., 
& Centanni, S. (2006). Anxiety and depression in COPD patients: The roles of gender 
and disease severity.Respiratory Medicine, 100, 1767-1774. 
Ref Type: Journal 
Dodd, M., Janson, S., Facione, N., Faucett, J., Froelicher, E. S., Humphreys, J., 
Lee, K., Miaskowski, C., Puntillo, K., Rankin, S., & Taylor, D. (2001a). Advancing the 
science of symptom management 
1.Journal of Advanced Nursing, 33, 668-676. 
Ref Type: Journal 
Dodd, M. J., Miaskowski, C., & Paul, S. M. (2001b). Symptom clusters and their 
effect on the functional status of patients with cancer 
4.Oncology Nursing Forum, 28, 465-470. 
Ref Type: Journal 
 84 
Dowson, C., Laing, R., Barraclough, R., Town, I., Mulder, R., Norris, K., & 
Drennan, C. (2001). The use of the Hospital Anxiety and Depression Scale (HADS) in 
patients with chronic obstructive pulmonary disease: a pilot study 
2.New Zealand Medical Journal, 114, 447-449. 
Ref Type: Journal 
Gay, C. L., Lee, K. A., & Lee, S. Y. (2004). Sleep patterns and fatigue in new 
mothers and fathers.Biol.Res.Nurs., 5, 311-318. 
Ref Type: Journal 
George, C. F. & Bayliff, C. D. (2003). Management of insomnia in patients with 
chronic obstructive pulmonary disease.Drugs, 63, 379-387. 
Ref Type: Journal 
Gift, A. G. (1990). Dyspnea.Nursing Clinics of North America, 25, 955-965. 
Ref Type: Journal 
Hardie, J. A., Vollmer, W. M., Buist, A. S., Bakke, P., & Morkve, O. (2005). 
Respiratory symptoms and obstructive pulmonary disease in a population aged over 70 
years.Respiratory Medicine, 99, 186-195. 
Ref Type: Journal 
Hurd, S. (2000). The impact of COPD on lung health worldwide: epidemiology 
and incidence.Chest, 117, 1S-4S. 
Ref Type: Journal 
Hynninen, M. J., Pallesen, S., & Nordhus, I. H. (2007). Factors affecting health 
status in COPD patients with co-morbid anxiety or 
depression.Int.J.Chron.Obstruct.Pulmon.Dis., 2, 323-328. 
Ref Type: Journal 
Jones, P. W., Quirk, F. H., Baveystock, C. M., & Littlejohns, P. (1992). A self-
complete measure of health status for chronic airflow limitation. The St. George's 
Respiratory Questionnaire 
1.American Review of Respiratory Disease, 145, 1321-1327. 
Ref Type: Journal 
Kapella, M. C., Larson, J. L., Patel, M. K., Covey, M. K., & Berry, J. K. (2006). 
Subjective fatigue, influencing variables, and consequences in chronic obstructive 
pulmonary disease 
1.Nursing Research, 55, 10-17. 
Ref Type: Journal 
Kara, M. & Mirici, A. (2004). Loneliness, depression, and social support of 
Turkish patients with chronic obstructive pulmonary disease and their 
spouses.J.Nurs.Scholarsh., 36, 331-336. 
Ref Type: Journal 
Kellner, R., Samet, J., & Pathak, D. (1992). Dyspnea, anxiety, and depression in 
chronic respiratory impairment.General Hospital Psychiatry, 14, 20-28. 
Ref Type: Journal 
 85 
Kinsman, R. A., Yaroush, R. A., Fernandez, E., Dirks, J. F., Schocket, M., & 
Fukuhara, J. (1983). Symptoms and experiences in chronic bronchitis and 
emphysema.Chest, 83, 755-761. 
Ref Type: Journal 
Klepstad, P., Loge, J. H., Borchgrevink, P. C., Mendoza, T. R., Cleeland, C. S., & 
Kaasa, S. (2002). The Norwegian brief pain inventory questionnaire: translation and 
validation in cancer pain patients.J.Pain Symptom.Manage., 24, 517-525. 
Ref Type: Journal 
Klinkenberg, M., Willems, D. L., van der, W. G., & Deeg, D. J. (2004). Symptom 
burden in the last week of life.J.Pain Symptom.Manage., 27, 5-13. 
Ref Type: Journal 
Klungsoyr, O., Nygard, J. F., Sorensen, T., & Sandanger, I. (2006). Cigarette 
smoking and incidence of first depressive episode: an 11-year, population-based follow-
up study 
1.American Journal of Epidemiology, 163, 421-432. 
Ref Type: Journal 
Larson, J. L., Ahijevych, K., Gift, A., Hoffman, L., Janson, S. L., Lanuza, D. M., 
Leidy, N. K., Meek, P., Roberts, J., Weaver, T., & Yoos, H. L. (2006). American 
Thoracic Society statement on research priorities in respiratory 
nursing.Am.J.Respir.Crit Care Med., 174, 471-478. 
Ref Type: Journal 
Lee, S. Y. (2007). Validating the General Sleep Disturbance Scale among Chinese 
American parents with hospitalized infants.Journal of Transcultural Nursing, 18, 111-
117. 
Ref Type: Journal 
Lin, M., Chen, Y., & McDowell, I. (2005). Increased risk of depression in COPD 
patients with higher education and income.Chron.Respir.Dis., 2, 13-19. 
Ref Type: Journal 
Lindsey, A. M., West, C. M., & Carrieri-Kohlman, V. (1993). Pathophysiological 
phenomena in nursing 
human responses to illness. (2nd ed ed.) Philadelphia: Saunders. 
Ref Type: Book, Whole 
Loge, J. H., Ekeberg, O., & Kaasa, S. (1998). Fatigue in the general Norwegian 
population: normative data and associations.J.Psychosom.Res., 45, 53-65. 
Ref Type: Journal 
MacIntyre, N. R. (2006). Muscle dysfunction associated with chronic obstructive 
pulmonary disease 
1.Respiratory Care, 51, 840-847. 
Ref Type: Journal 
 
 86 
Mahler, D. A., Faryniarz, K., Tomlinson, D., Colice, G. L., Robins, A. G., 
Olmstead, E. M., & O'Connor, G. T. (1992). Impact of dyspnea and physiologic function 
on general health status in patients with chronic obstructive pulmonary disease.Chest, 
102, 395-401. 
Ref Type: Journal 
Mahler, D. A. & Mackowiak, J. I. (1995). Evaluation of the short-form 36-item 
questionnaire to measure health-related quality of life in patients with COPD 
2.Chest, 107, 1585-1589. 
Ref Type: Journal 
Marks, G. B., Burney, P. G., Premaratne, U. N., Simpson, J., & Webb, J. (1997). 
Asthma in Greenwich, UK: impact of the disease and current management 
practices.European Respiratory Journal, 10, 1224-1229. 
Ref Type: Journal 
Marks, G. B., Dunn, S. M., & Woolcock, A. J. (1992). A scale for the 
measurement of quality of life in adults with asthma.Journal of Clinical Epidemiology, 
45, 461-472. 
Ref Type: Journal 
McBeth, J. & Jones, K. (2007). Epidemiology of chronic musculoskeletal 
pain.Best.Pract.Res.Clin.Rheumatol., 21, 403-425. 
Ref Type: Journal 
Miaskowski, C., Aouizerat, B. E., Dodd, M., & Cooper, B. (2007). Conceptual 
issues in symptom clusters research and their implications for quality-of-life assessment 
in patients with cancer.J.Natl.Cancer Inst.Monogr, 39-46. 
Ref Type: Journal 
Miaskowski, C., Cooper, B. A., Paul, S. M., Dodd, M., Lee, K., Aouizerat, B. E., 
West, C., Cho, M., & Bank, A. (2006). Subgroups of patients with cancer with different 
symptom experiences and quality-of-life outcomes: a cluster analysis 
2.Oncology Nursing Forum, 33, E79-E89. 
Ref Type: Journal 
Miaskowski, C., Dodd, M., & Lee, K. (2004). Symptom clusters: the new frontier 
in symptom management research 
4.J.Natl.Cancer Inst.Monogr, 17-21. 
Ref Type: Journal 
Miaskowski, C. & Lee, K. A. (1999). Pain, fatigue, and sleep disturbances in 
oncology outpatients receiving radiation therapy for bone metastasis: a pilot 
study.J.Pain Symptom.Manage., 17, 320-332. 
Ref Type: Journal 
Miaskowski, C., Paul, S. M., Cooper, B. A., Lee, K., Dodd, M., West, C., 
Aouizerat, B. E., Swift, P. S., & Wara, W. (2008). Trajectories of fatigue in men with 
prostate cancer before, during, and after radiation therapy.J.Pain Symptom.Manage., 
35, 632-643. 
Ref Type: Journal 
 87 
Mikkelsen, R. L., Middelboe, T., Pisinger, C., & Stage, K. B. (2004). Anxiety and 
depression in patients with chronic obstructive pulmonary disease (COPD). A review 
2.Nord.J.Psychiatry, 58, 65-70. 
Ref Type: Journal 
Mishima, M., Oku, Y., Muro, S., Hirai, T., Chin, K., Ohi, M., Nakagawa, M., 
Fujita, M., Sato, K., Shimada, K., Yamaoka, S., Oda, Y., Asai, N., Sagawa, Y., & Kuno, 
K. (1996). Relationship between dyspnea in daily life and psycho-physiologic state in 
patients with chronic obstructive pulmonary disease during long-term domiciliary 
oxygen therapy 
2.Internal Medicine, 35, 453-458. 
Ref Type: Journal 
Mohsenin, V. (2005). Sleep in chronic obstructive pulmonary 
disease.Semin.Respir.Crit Care Med., 26, 109-116. 
Ref Type: Journal 
Orozco-Levi, M. (2003). Structure and function of the respiratory muscles in 
patients with COPD: impairment or adaptation? 
7.Eur.Respir.J.Suppl, 46, 41s-51s. 
Ref Type: Journal 
Ozge, A., Ozge, C., Kaleagasi, H., Yalin, O. O., Unal, O., & Ozgur, E. S. (2006). 
Headache in patients with chronic obstructive pulmonary disease: effects of chronic 
hypoxaemia 
3.J.Headache Pain, 7, 37-43. 
Ref Type: Journal 
Pallant, J. (2005). SPSS survival manual 
a step by step guide to data analysis using SPSS for Windows (Version 12). (2nd ed ed.) 
Maidenhead: Open University Press. 
Ref Type: Book, Whole 
Paul, S. M., Zelman, D. C., Smith, M., & Miaskowski, C. (2005). Categorizing the 
severity of cancer pain: further exploration of the establishment of cutpoints.Pain, 113, 
37-44. 
Ref Type: Journal 
Pellegrino, R., Viegi, G., Brusasco, V., Crapo, R. O., Burgos, F., Casaburi, R., 
Coates, A., van der Grinten, C. P., Gustafsson, P., Hankinson, J., Jensen, R., Johnson, D. 
C., MacIntyre, N., McKay, R., Miller, M. R., Navajas, D., Pedersen, O. F., & Wanger, J. 
(2005). Interpretative strategies for lung function tests.European Respiratory Journal, 
26, 948-968. 
Ref Type: Journal 
Rabe, K. F., Hurd, S., Anzueto, A., Barnes, P. J., Buist, S. A., Calverley, P., 
Fukuchi, Y., Jenkins, C., Rodriguez-Roisin, R., van, W. C., & Zielinski, J. (2007). Global 
strategy for the diagnosis, management, and prevention of chronic obstructive 
pulmonary disease: GOLD executive summary.Am.J.Respir.Crit Care Med., 176, 532-
555. 
Ref Type: Journal 
 88 
Reishtein, J. L. (2005). Relationship between symptoms and functional 
performance in COPD.Research in Nursing and Health, 28, 39-47. 
Ref Type: Journal 
Rustoen, T., Wahl, A. K., Hanestad, B. R., Lerdal, A., Paul, S., & Miaskowski, C. 
(2004). Prevalence and characteristics of chronic pain in the general Norwegian 
population 
2.Eur.J.Pain, 8, 555-565. 
Ref Type: Journal 
Schlecht, N. F., Schwartzman, K., & Bourbeau, J. (2005). Dyspnea as clinical 
indicator in patients with chronic obstructive pulmonary disease.Chron.Respir.Dis., 2, 
183-191. 
Ref Type: Journal 
Sirey, J. A., Raue, P. J., & Alexopoulos, G. S. (2007). An intervention to improve 
depression care in older adults with COPD.International Journal of Geriatric 
Psychiatry, 22, 154-159. 
Ref Type: Journal 
Stavem, K., Erikssen, J., & Boe, J. (1999). Performance of a short lung-specific 
health status measure in outpatients with chronic obstructive pulmonary disease 
1.Respiratory Medicine, 93, 467-475. 
Ref Type: Journal 
Stenseth, G., Bjornnes, M., Kaasa, S., & Klepstad, P. (2007). Can cancer patients 
assess the influence of pain on functions? A randomised, controlled study of the pain 
interference items in the Brief Pain Inventory 
1.BMC.Palliat.Care, 6, 2. 
Ref Type: Journal 
Theander, K. & Unosson, M. (2004). Fatigue in patients with chronic obstructive 
pulmonary disease 
2.Journal of Advanced Nursing, 45, 172-177. 
Ref Type: Journal 
van Manen, J. G., Bindels, P. J., Dekker, E. W., Ijzermans, C. J., Bottema, B. J., 
van der Zee, J. S., & Schade, E. (2001). Added value of co-morbidity in predicting 
health-related quality of life in COPD patients.Respiratory Medicine, 95, 496-504. 
Ref Type: Journal 
van Manen, J. G., Bindels, P. J., Dekker, F. W., Bottema, B. J., van der Zee, J. S., 
Ijzermans, C. J., & Schade, E. (2003). The influence of COPD on health-related quality 
of life independent of the influence of comorbidity 
1.Journal of Clinical Epidemiology, 56, 1177-1184. 
Ref Type: Journal 
van Manen, J. G., Bindels, P. J., Dekker, F. W., Ijzermans, C. J., van der Zee, J. 
S., & Schade, E. (2002). Risk of depression in patients with chronic obstructive 
pulmonary disease and its determinants.Thorax, 57, 412-416. 
Ref Type: Journal 
 89 
Vestbo, J., Knudsen, K. M., & Rasmussen, F. V. (1988). Should we continue using 
questionnaires on breathlessness in epidemiologic surveys?American Review of 
Respiratory Disease, 137, 1114-1118. 
Ref Type: Journal 
Voss, J. G., Dodd, M., Portillo, C., & Holzemer, W. (2006). Theories of fatigue: 
application in HIV/AIDS.Journal of the Association of Nurses in AIDS Care, 17, 37-50. 
Ref Type: Journal 
Walke, L. M., Byers, A. L., Tinetti, M. E., Dubin, J. A., McCorkle, R., & Fried, T. 
R. (2007). Range and severity of symptoms over time among older adults with chronic 
obstructive pulmonary disease and heart failure.Archives of Internal Medicine, 167, 
2503-2508. 
Ref Type: Journal 
Webster dictionary. (1983). Webster's ninth new collegiate dictionary. 
Springfield, Mass: Merriam-Webster. 
Ref Type: Book, Whole 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 90 
 
 
In the period 
01.06.2005-02.05.2006 
 
502  
COPD patients registered at the clinic 
56 subjects had no confirmed COPD in the journal 
11 persons with unknown address 
48 persons dead 
387 persons invited in the period 
June 2006 - December 2007 
168 agreed to participate 
2  persons were not able to fill out the questionnaire 
6  persons withdrew their acceptance 
2  persons did not deliver the questionnaire 
4  persons did not meet up to the appointment 
29 persons declined to participate 
190 persons did not answer 
 
154 persons participated 
Figure 1- Flowchart 
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Table 1- Demographic Characteristics of patients with COPD (N=154) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 ¹ The total is more than 100% because some participants had from 0-7 diseases 
² The total is more than 100% because some had pain several places. Results from BPI. 
 
         N     % 
Age   Mean ( SD)  64,6 (10,2)    
          Min –Max    36-87 
 
Gender 
Male  
Women  
 
79  (51,3%) 
75  (48,7%) 
Marital status 
Married/partner  
Widow 
Other  
 
68 (44,2%) 
25 (16.2%) 
61 (39.6%) 
Smoking history 
No Smoker 
Smoker   
 
86 (44.2%) 
68 (43.5%) 
Work 
Working  
Retired   
Disability insurance  
 
41 (26,6%) 
67 (43,5%) 
41 (26,6%) 
Living 
Living alone (%) 
Living with spouse or partner 
Living with others 
 
77 (50%) 
69 (44,8%) 
19 (12,3%) 
Education 
Primary school   
Vocational school  
Secondary school  
University <4 year  
University > 4 year  
 
35 (22,7%) 
27 (17,5%) 
47 (30,5%) 
28 (18,2%) 
15 (9,7%) 
Co morbidity¹ 
Heart disorders 
Blood pressure 
Diabetes 
Stomach and kidney disorder 
Stroke 
Cancer 
Psychiatric disorders 
Sum joint disorders 
Asthma 
Other lung diseases  
Other diseases 
 
48 (31,2%) 
60 (39%) 
18 (11,7%) 
26 (16.9%) 
10 (6,5) 
14 (9,1%) 
15 (9,7%) 
34 (22.1%) 
13 (8,4%) 
22 (14,3%) 
16 (10.4%) 
Amount Co-morbidity 
0 disease 
1 disease 
2 diseases 
3 diseases 
4 diseases 
5 diseases 
6 diseases 
7 diseases 
 
29 (18.8%) 
37 (24%) 
39 (25.3%) 
31 (20.1%) 
11 (7.1%) 
4 (2.6%) 
2 (1.3)  
1(0.6%) 
Parts of the body with pain² 
Shoulders 
Neck 
Legs 
Thighs 
Back 
Lumbar region 
Head 
 
51(33%) 
26 (16.9%) 
41 (26.6%) 
25 (16.2%) 
33 (21.4%) 
45 (29.2%) 
19 (12.3%) 
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Table 2-Descriptive information from tests and questionnaires 
 N  % Mean SD Min-Max Score form- to 
FEV1%  
 
154  59,1 22,6 17-124  
Mild stage  28  18.2     
Moderate stage 72  46.8     
Severe stage 39 25.3     
Very severe stage 15  9.7  
 
   
FEV%  154  55,1 13,2 24-82  
Breathlessness 153  2.4 2,1 0-7.5 0-10 
Fatigue 153  3.7 1.7 0-9,6 0-10 
Anxiety      153  6,2 4,5 0.5-18 0-21 
Depression      153  5,4 3,6 0-16 0-21 
Insomnia 154  61.3 21.9 16.8-115.5 0-147 
Pain interference            152  21.2 18.0 0-64 0-70 
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Appendix B- Questionnaire (the questionnaires used in the master thesis only) 
 
 
 
 
 
 
 
Spørreskjema om 
sykdom, forventet mestring og livskvalitet 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Universitet i Oslo 
Institutt for sykepleiervitenskap og helsefag 
 
 
 
 
 
 
 
 
 
 
Kandidat nr.  
      
Dato:  
         
 100 
 
 
 
 
 
A1. ALDER:_____       
  
 
A2. KJØNN 
 
Mann:   Kvinne:  
 
 
 
A3. SPØRSMÅL OM SIVILSTAND 
 
Gift/ samboer:        
Ugift:         
Enke/Enkemann:         
Skilt:         
Separert:    
 
   
 
A4. SPØRSMÅL OM HVEM DU BOR SAMMEN MED 
 
Bor alene:           
Ektefelle/samboer:          
Søsken:           
Annen familie/slekt:        
Barn/svigerbarn:     
Bor på institusjon:          
Andre:           
 
 
 
A5. SPØRSMÅL OM UTDANNING 
 
Kryss av for høyest gjennomførte utdanning: 
 
Grunnskole:            
Yrkesskole:            
Videregående skole:           
Høyskole/universitetsutdannelse mindre enn 3-4 år:      
Høyskole/universitetsutdannelse over 4 år:    
 
DEL A: BAKGRUNNSOPPLYSNINGER 
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A6. SPØRSMÅL OM JOBB 
 
1.  Er du pr. dags dato i lønnet arbeid?  Ja:   Nei:  
 
2.   Hvis ja, hva jobber du med?_____________________________________________________ 
 
3.  Hvis ja, hvor stor stillingsprosent har du?___________________________________________ 
 
4.  Hvis nei: 
Pensjonist:     Uføretrygdet:     Hjemmeværende:    Går på skole:     Sykemeldt:  
 
5.  Hva har du eventuelt jobbet med tidligere?__________________________________________ 
 
 
A7. SPØRSMÅL OM HENDELSER I LIVET 
 
Kryss av i en eller flere av rutene nedenfor dersom  du i din senere tid (siste 4 uker) har 
opplevd noen av følgende hendelser: 
 
Fått barn:   
Giftet deg/flyttet sammen  med samboer:   
Dødsfall i familien /nære venner:   
Alvorlige bomessige eller økonomiske problemer:   
Andre betydelige livshendelser:    Beskriv:_________________________________ 
      
 
 
B1. SPØRSMÅL OM MEDISINER 
 
Bruker du medisinene dine regelmessig hver dag? Ja   Nei   
 
 
 
B2. SPØRSMÅL OM RØYKING 
 
1.  Røyker du?    Ja:   Nei:  
 
Dersom ja, hvor lenge har du røkt i antall år?__________________________________________ 
 
Dersom ja, hvor mange sigaretter røyker du hver dag?__________________________________ 
 
 
2.   Dersom Nei, har du røkt tidligere? Ja   Nei    
 
3.  Hvor lenge er det siden du eventuelt sluttet? _____________________________________ 
DEL B: OPPLYSNINGER OM SYKDOM OG FAKTORER RUNDT 
SYKDOM 
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B3. SPØRSMÅL OM OPPLÆRING PÅ SYKDOM OG TRENING 
 
1.  Har du deltatt på lungerehabilitering? Ja:   Nei:   
 
2. Dersom ja, hvor lenge siden?   
1-6 måneder siden:    6 måneder til 1 år siden:     1-3 år siden    Mer enn 3 år siden:  
 
3. Har du deltatt på annen kurs eller undervisning om din KOLS?    Ja:  Nei:  
 
Dersom ja, spessifiser:_____________________________________________________________ 
 
4. Har du fått opplæring av helsepersonell om din lungesykdom?      Ja:    Nei:  
 
Dersom ja, kryss av i en eller flere av rutene av hvem du har fått opplæring av? 
      
Fast lege:      Lungelege:       Sykepleier:       Fysioterapeut:  Ergoterapeut:  
 
 
5. Kryss av i en eller flere av rutene om du er i aktivitet i form av: 
 
Gå tur:    Fysikalskinstitutt:   Hjemmeøvelser:   Helsestudio  Annet ________ 
 
_____________________________________________________________________________ 
 
6. Hvor ofte  er du i aktivitet: 
 
Mindre enn 2 ganger i måneden      
Fra 2-4 ganger i måneden    
En gang i uken  
2-3 ganger i uken   
Mer enn 3 gagner i uken  
 
 
 
B4. SPØRSMÅL OM KOLS 
 
1. Har du hatt lungebetennelse eller forkjølelse de siste 4 ukene? Ja   Nei   
 
2. Har du vært hos lege på grunn av din KOLS det siste året? Ja   Nei   
Eventuelt hvor mange ganger?______________________________________ 
       
      4.    Har du hatt sykehusinnleggelse det siste året? Ja   Nei   
 Eventuelt hvor mange ganger?______________________________________ 
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B5. SPØRSMÅL OM LUNGESYKDOMMEN  
Nedenfor følger en serie utsagn, som beskriver hvordan astma og obstruktiv 
lungesykdom (eller sykdommens behandling) affiseres for noen personer.  For hvert 
utsagn ber vi deg merke av det svaret som passer best for deg i løpet av de siste fire 
ukene. Sett ring rundt svaret. 
 
 Ikke i det 
hele tatt 
Lett Middels Mye Svært 
mye 
1. Jeg har vært plaget av episoder med 
kortpustethet 
     1     2     3     4     5 
2. Jeg har vært plaget av anfall med 
pipende pustelyd 
     1     2     3     4     5 
3. Jeg har vært plaget av en følelse av 
tranghet i brystet 
     1     2     3     4     5 
4. Jeg har vært hindret i å gå bortover gaten 
på flat mark eller i å gjøre lett husarbeid 
pga lungesykdommen 
     1     2     3     4     5 
5. Jeg har vært hindret i å gå oppoverbakke 
eller å gjøre tungt husarbeid pga. 
lungesykdommen 
     1     2     3     4     5 
6. Jeg har følt meg trett eller generelt 
manglet energi 
     1     2     3     4     5 
7. Jeg har vært ute av stand til å sove om 
natten 
     1     2     3     4     5 
8. Jeg har følt meg trist eller deprimert      1     2     3     4     5 
9. Jeg har vært frustrert pga meg selv      1     2     3     4     5 
10. Jeg har vært engstelig, spent eller 
stresset 
     1     2     3     4     5 
11. Jeg har følt at lungesykdommen 
forhindrer meg i å utføre det jeg ønsker i 
livet 
     1     2     3     4     5 
12. Lungesykdommen har forstyrret mitt 
sosiale liv 
     1     2     3     4     5 
13. Jeg har unngått å gå til bestemte steder 
fordi de er dårlige for min lungesykdom 
     1     2     3     4     5 
14. Jeg har unngått å gå til bestemte steder 
fordi jeg har vært redd for å få et anfall 
med pustebesvær og ikke være i stand til å 
få hjelp 
     1     2     3     4     5 
15. Jeg har måttet begrense meg i sport, 
hobbyer eller andre fritidsaktiviteter jeg 
kan delta I pga. min lungesykdom 
     1     2     3     4     5 
16. Jeg har følt at jeg generelt må begrense 
meg 
     1     2     3     4     5 
17. Jeg har følt at lungesykdommen 
kontrollerer livet mitt 
     1     2     3     4     5 
18. Jeg har vært bekymret for min 
nåværende eller fremtidige helse pga. 
lungesykdommen 
     1     2     3     4     5 
19. Jeg har vært bekymret for at 
lungesykdommen kan forkorte mitt liv 
     1     2     3     4     5 
20. Jeg har følt meg avhengig av mine 
astma/KOLS medisiner 
     1     2     3     4     5 
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Vi ønsker å vite mer om energinivået ditt. Nedenfor er det 18 utsagn vi ber deg svare på.  
Dette vil ta deg mindre enn ett minutt å gjøre.  
INSTRUKSJONER: For hvert av utsagnene nedenfor: sett ring rundt det tallet som best indikerer  
hvordan du føler deg AKKURAT NÅ (angi klokkeslett: ____:____) 
 
 
 
 
 
 
 
 
 
 
 
     VENNLIGST SVAR PÅ FØLGENDE UTSAGN OM HVORDAN DU FØLER DEG  
     AKKURAT NÅ: 
 
1. ikke sliten i           svært  
      det hele tatt  0      1      2      3      4      5      6      7      8      9      10  sliten 
 
2. ikke trøtt i           svært 
      det hele tatt  0      1      2      3      4      5      6      7      8      9      10  trøtt 
 
3. ikke døsig           svært 
i det hele tatt  0      1      2      3      4      5      6      7      8      9      10  døsig 
 
4. ikke utmattet          svært 
i det hele tatt  0      1      2      3      4      5      6      7      8      9      10  utmattet 
 
5. ikke utslitt           svært 
i det hele tatt  0      1      2      3      4      5      6      7      8      9      10  utslitt 
 
6. ikke utkjørt           svært 
i det hele tatt  0      1      2      3      4      5      6      7      8      9      10  utkjørt 
 
7. ikke utslått           svært 
i det hele tatt  0      1      2      3      4      5      6      7      8      9      10  utslått 
 
 8. å holde øynene          å holde 
åpne er ikke           øynene åpne 
anstrengende  0      1      2      3      4      5      6      7      8      9      10  er veldig 
       i det hele tatt           anstrengende 
For eksempel: Anta at du ikke har spist siden i går. Vil du være ”ikke sulten i det hele tatt”, 
eller vil du være nærmere ”svært sulten” helt til høyre på skalaen? Hvilket tall nedenfor vil 
du sette ring rundt? 
 
ikke sulten i                svært 
det hele tatt     0      1      2      3      4      5      6      7      8      9      10   sulten 
 
Du vil antakeligvis sette ring rundt et tall nærmere ”svært sulten” helt til høyre på skalaen, 
slik dette eksempelet viser: 
 
ikke sulten i               svært 
det hele tatt    0      1      2      3      4      5      6      7      8              10   sulten 
 
9 
DEL C: SPØRSMÅL OM HVOR TRØTT, DØSIG OG UTMATTET DU ER 
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9. å bevege           å bevege  
kroppen er ikke          kroppen er  
       anstrengende i  0      1      2      3      4      5      6      7      8      9      10  veldig 
det hele tatt           anstrengende 
 
10. å konsentrere          å konsentrere 
seg er ikke           seg er veldig 
anstrengende  0      1      2      3      4      5      6      7      8      9      10      anstrengende 
i det hele tatt 
 
11. å holde i gang en          å holde i gang 
samtale er ikke          en samtale er 
       anstrengende 0      1      2      3      4      5      6      7      8      9      10  veldig 
       i det hele tatt          anstrengende 
 
12.  Jeg har absolutt          jeg har et  
ikke noe behov          veldig sterkt 
for å lukke  0      1      2      3      4      5      6      7      8      9      10  behov for å  
øynene           lukke øynene 
 
13. jeg har absolutt          jeg har et 
ikke noe behov          veldig sterkt 
for å legge meg 0      1      2      3      4      5      6      7      8      9      10  behov for å                              
nedpå           legge meg 
            nedpå 
INDIKER HVORDAN DU FØLER DEG AKKURAT NÅ I FORHOLD TIL DE SISTE FEM  
UTSAGNENE: 
 
14. ikke energisk          svært 
i det hele tatt  0      1      2      3      4      5      6      7      8      9      10  energisk 
 
15. ikke aktiv           svært 
i det hele tatt  0      1      2      3      4      5      6      7      8      9      10  aktiv 
 
16. ikke sprek           svært 
i det hele tatt  0      1      2      3      4      5      6      7      8      9      10  sprek 
  
17. ikke effektiv           svært 
i det hele tatt  0      1      2      3      4      5      6      7      8      9      10  effektiv 
 
18. ikke livlig            svært 
i det hele tatt  0      1      2      3      4      5      6      7      8      9      10  livlig 
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                        DEL D: SPØRSMÅL OM SØVNFORSTYRRELSE 
 
Tenk tilbake på den siste uken. Hvor mange dager har du (sett ring rundt det 
aktuelle tall): 
 
                                             
1. Hatt problemer med å sovne 
 
 
0 
 
1 
 
2 
 
3 
 
4 
 
5 
 
6 
 
7 
2. Våknet i løpet av søvnperioden 
 
 
0 
 
1 
 
2 
 
3 
 
4 
 
5 
 
6 
 
7 
3. Våknet for tidlig og fikk ikke til å 
sovne igjen  
 
0 
 
1 
 
2 
 
3 
 
4 
 
5 
 
6 
 
7 
4. Følt deg uthvilt når du våkner på 
slutten av en søvnperiode 
 
0 
 
1 
 
2 
 
3 
 
4 
 
5 
 
6 
 
7 
5. Sovet dårlig 
 
 
0 
 
1 
 
2 
 
3 
 
4 
 
5 
 
6 
 
7 
6. Følt deg søvnig i løpet av dagen 
 
 
0 
 
1 
 
2 
 
3 
 
4 
 
5 
 
6 
 
7 
7. Kjempet for å holde deg våken 
gjennom dagen 
 
0 
 
1 
 
2 
 
3 
 
4 
 
5 
 
6 
 
7 
8. Følt deg irritabel i løpet av dagen 
 
 
0 
 
1 
 
2 
 
3 
 
4 
 
5 
 
6 
7 
9. Følt deg trøtt eller utmattet i løpet 
av dagen 
 
0 
 
1 
 
2 
 
3 
 
4 
 
5 
 
6 
 
7 
10. Følt deg tilfreds med 
søvnkvaliteten 
 
0 
 
1 
 
2 
 
3 
 
4 
 
5 
 
6 
 
7 
11. Følt deg våken og energisk 
gjennom dagen 
 
0 
 
1 
 
2 
 
3 
 
4 
 
5 
 
6 
 
7 
12. Fått for mye søvn 
 
 
0 
 
1 
 
2 
 
3 
 
4 
 
5 
 
6 
 
7 
13. Fått for lite søvn 
 
 
0 
 
1 
 
2 
 
3 
 
4 
 
5 
 
6 
 
7 
14. Tatt en blund til planlagt tid 
 
 
0 
 
1 
 
2 
 
3 
 
4 
 
5 
 
6 
 
7 
15. Sovnet uten at det var planlagt 
 
 
0 
 
1 
 
2 
 
3 
 
4 
 
5 
 
6 
 
7 
16. Drukket alkohol for å få til å sovne 
 
 
0 
 
1 
 
2 
 
3 
 
4 
 
5 
 
6 
 
7 
17. Brukt tobakk for å få til å sovne 
 
 
0 
 
1 
 
2 
 
3 
 
4 
 
5 
 
6 
 
7 
18. Brukt andre stimuli for å sovne 
(f.eks. avslapping, musikk, lesing)  
 
0 
 
1 
 
2 
 
3 
 
4 
 
5 
 
6 
 
7 
19. Brukt naturmedisinske midler for å 
sovne 
 
0 
 
1 
 
2 
 
3 
 
4 
 
5 
 
6 
 
7 
20. Brukt reseptbelagt sovemedisin for 
å få til å sovne 
 
0 
 
1 
 
2 
 
3 
 
4 
 
5 
 
6 
 
7 
21. Brukt paracet eller annet 
smertestillende for å sove 
 
0 
 
1 
 
2 
 
3 
 
4 
 
5 
 
6 
 
7 
 Aldri Hver dag 
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Appendix C – Information and invitation letter 
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Appendix D – Approval form from the participants 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Appendix C- Approval from the Medical Ethics Committee  
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Appendix E- Approval form from the Medical Ethics Committee 
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Appendix F- Approval from Data Inspectorate 
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Appendix G- Approval from the Medical Clinic 
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Appendix H- Approval form Medical Ethics Committee for collecting data on                 
non-participants 
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